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Abstract 
Cancer is a malignant neoplastic tissue. The pyrimidine analogue 5-fluorouracil is an 
anticancer drug used against several types of cancer. It owes its specificity against 
neoplasms due to the higher rate of nutrient uptake, RNA and DNA synthesis, and in 
particular the higher rate of nucleobase scavenging and salvage of neoplastic cells. 
However, tumours can develop resistance to 5-fluorouracil and other anticancer drugs, 
rendering the therapy useless. Due to genetic variation, humans can also be inherently 
more or less sensitive to 5-fluorouracil and other anticancer drugs such as the purine 
analogue mercaptopurine. 
In this thesis I have investigated the mechanisms of resistance to 5-fluorouracil and 
the model purine analogue 6-N-hydroxylaminopurine in the budding yeast 
Saccharomyces cerevisiae. The mechanisms found to confer resistance in S. cerevisiae 
to 5-fluorouracil and 6-N-hydroxylaminopurine included both deregulation of the de 
novo synthesis of nucleotides, and detoxification of non-canonical nucleotides. I 
proceeded to study genetic interactions between genes involved in resistance to both 5-
fluorouracil and 6-N-hydroxylaminopurine by using plasmid overexpression in yeast 
strains knocked out for different resistance genes and other genes involved in 
nucleotide metabolism. 
HAM1 is a yeast gene coding for a nucleotide pyrophosphatase, the overexpression 
of which we found to confer resistance to both 5-fluorouracil and 6-N-
hydroxylaminopurine. HAM1 has a human homologue called ITPA. We proceeded to 
test if a known genetic polymorphism in ITPA could help predict toxicity in patients 
receiving a chemotherapeutic regimen including 5-fluorouracil. Our results suggest that 
loss of ITPA function may lead to increased sensitivity to 5-fluorouracil. 
We have also investigated the mechanism of transcriptional regulation by the yeast 
Rph1p protein, a zinc finger transcription factor which also contains a jmjC domain 
with histone demethylase activity. Rph1p functions downstream of the RAS-cAMP-
PKA pathway and several other nutrient sensing pathways. We found, surprisingly, that 
the histone demethylase activity of Rph1p is largely dispensable for its role in 
transcriptional regulation. 
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The budding yeast Saccharomyces cerevisiae, a eukaryotic microorganism, got 
its genus and species names from the Latin words for 'sugar fungus' and beer. It 
is also named 'budding yeast' in the scientific literature due to the fact that it 
has an asymmetric cell division, where a small daughter cell buds off the larger 
mother cell. It is however most widely known as just 'yeast', since it is the 
yeast used in human culture to make bread, wine and beer since ancient times. 
Even more ancient is the time point when the ancestors of humans and S. 
cerevisiae diverged. It is estimated to have taken place more than 1.2 billion 
years ago (Wu et al., 1986). 
The laboratory strains of budding yeast are often single cells when grown in 
liquid culture, and form round smooth colonies when grown on solid media. 
However, at least some strains of S. cerevisiae also have the capacity to form 
biofilms or invasive pseudohyphae on solid media and can form multicellular 
aggregates (flocculate) in liquid culture (Reynolds and Fink, 2001; Smukalla et 
al., 2008). 
S. cerevisiae can be easily propagated both in its haploid and in its diploid 
form. A diploid strain is generated by mating of two haploid strains with 
opposite mating types. A haploid strain is regenerated when the diploid 
sporulates (i.e. goes through meiosis). This sexual life cycle facilitates the 
construction of yeast strains with new genotypes since new combinations of 
mutations or gene knockouts can be generated by mating of single mutant 
haploids and sporulation, after which double mutant haploids can be recovered 
by tetrad dissection. The efficient homologous recombination of S. cerevisiae 
makes it relatively easy to both knock in and knock out chromosomal genes. 
New genes and multiple copies of existing genes can also be introduced by 
transformation of yeast cells with shuttle plasmids or yeast artificial 
chromosomes (YACs). 
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The genome of S. cerevisiae has been fully sequenced and contains about 
6000 genes, whereof about 20% are essential and 3% show haploinsufficiency 
(a growth deficiency of heterozygous wild type/knockout mutant diploids) on 
standard rich media (Deutschbauer et al., 2005; Goffeau et al., 1996). The 
Saccharomyces Genome Deletion Project made start to stop codon deletions of 
all non-essential yeast genes, in which the open reading frame was replaced by 
a uniquely tagged kanMX module, which confers kanamycin resistance. The 
project generated both homo- and heterozygous knockout strain libraries, 
which have greatly facilitated the discovery of gene functions and phenotypes 
(Kelly et al., 2001). 
1.1 Chemical genetics and drug discovery in yeast 
Around 2700 of the 6000 predicted S. cerevisiae proteins have human 
homologues with e-values less than 10-10 when blasted against the 
corresponding yeast protein. Several hundred of these predicted human 
orthologues of yeast genes have been implicated in human diseases. 
Significantly, drugs targeting human proteins may also inhibit the 
corresponding yeast orthologue, e.g. lovastatin which inhibits sterol 
biosynthesis both in human cells and in yeast. Yeast can therefore be used as a 
tool to discover new drugs for use in humans, at least when the targeted 
processes or enzymes are conserved between the two organisms. 
The cellular processes that are most highly conserved between humans and 
yeast are the primary metabolism, protein synthesis, cell division, intracellular 
transport, and DNA synthesis and repair. This implies that yeast can be useful 
as a tool for studying cancer and cytostatic drugs, to the extent that cancer is 
viewed as a cell division disorder (Hughes, 2002). 
One purpose of chemical genetics is to find macromolecular targets of small 
molecules. By modulating the functions of such macromolecules, using small 
molecules, one can bring about cellular changes in signal transduction, enzyme 
activities and cellular organization. The interactions between small molecules 
and macromolecules can be studied from two different perspectives. The focus 
could thus either be on a small molecule and which kind of effect it causes to 
the cell, or on a macromolecule, whose function could potentially be altered by 
some small molecule. The strategies to find an interaction are different 
depending on which perspective one has. If the mechanism behind the growth 
inhibition caused by a small molecule is sought, one could use HIP, HOP or 
resistance screens, as described below. In contrast, if one wants to find a small 
molecule that inhibits the function of a specific macromolecule, HIP could be 
used to screen a chemical library for potential inhibitors. 
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1.1.1 Haploinsufficiency profiling 
Haploinsufficiency profiling (HIP) is a technique used to identify proteins 
whose functions are affected by a specific condition. This is done by looking 
for growth defects of yeast strains that are heterozygous for different gene 
deletions under a specific condition, e.g. the exposure to a small molecule 
inhibitor. This kind of growth defect due to a 50% reduced gene dosage (as 
compared to the homozygous wild type strain) is called haploinsufficiency. 
The technique can also be used the other way around, to screen for a specific 
condition that inhibits the growth of a yeast strain that is heterozygous for a 
given gene knockout.  
HIP can be massively parallelized by pooling genetically marked (“bar 
coded”) yeast strains during growth and testing, followed by a microarray 
analysis to determine which strains survived in the presence of the drug and 
which strains did not (Giaever et al., 2004). 
The HIP technique only works if one can find conditions where the strain 
that is heterozygous for the deleted gene has a growth defect, as compared to 
the wild type strain. For example, to find an inhibitor of the Ura2p enzyme, one 
could compare the growth of the heterozygous URA2/ura2 strain and the wild 
type URA2/URA2 strain in media devoid of uracil (which requires Ura2p 
function), with and without a potential inhibitor of Ura2p. 
1.1.2 Homozygous deletion profiling 
The homozygous deletion profiling (HOP) technique is similar to HIP in set-
up, but different in interpretation. In the HOP assay one compares the growth 
of a haploid wild type strain to that of a haploid strain where the single copy of 
a specific gene has been knocked out. If the knockout strain has a growth 
defect under a specific condition, it cannot be due to the condition inhibiting 
the knocked out protein, since the protein is not there.  
It is, however, still possible to find clues to the target of the condition, since 
the knocked out protein whose absence causes an increased sensitivity to the 
condition may act in redundancy or in synergy with an unknown target that is 
directly affected by the condition.  
For example one could hypothetically find that arginine inhibits the growth 
of a strain defective in the carbamoyl phosphate synthetase subfunction of 
Ura2p, since arginine represses the functionally redundant carbamoyl 
phosphate synthetase function of the Cpa1p/Cpa2p complex (Lacroute et al., 
1965). 
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1.1.3 Plasmid overexpression screens for genetic suppression and resistance 
Under a condition where wild type or mutant cells have a growth inhibited 
phenotype, one can also find the protein affected by the condition, or other 
proteins which can rescue the growth defect when overexpressed, by 
transforming the cells with a yeast genomic library made in a high copy 
number plasmid. 
In the scenario where the condition is the exposure to an enzyme inhibitor, 
either the overexpression of the inhibited enzyme, a compensatory enzyme, or 
a detoxifying enzyme would be expected to restore growth. In the screen in 
publication I for 5-fluorouracil (5-FU) resistance, we did not isolate strains that 
overexpressed Cdc21p, thymidylate synthetase, which is inhibited by 5-FU. 
However, we isolated strains overexpressing genes, HAM1 and YJL055w,    
known and expected respectively to be involved in detoxification of non-
canonical nucleotides. 
Overexpressor screens can also be employed to find suppressor genes, i.e. 
genes whose overexpression compensates a reduced viability resulting from the 
loss or mutation of a given protein. With this approach it is for example 
possible to find proteins acting downstream in the signalling pathway of the 
targeted protein, or subunits in the protein complex which the protein is part of. 
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2 The cell cycle and nutrient signalling 
The progression of the cell cycle can be divided into four phases designated 
G1, S, G2 and M. The G1, S and G2 phases are sometimes collectively called 
the interphase, while the M-phase is composed of mitosis and cytokinesis. S. 
cerevisiae has an asymmetrical cytokinesis i.e. a cell division where the larger 
mother cell buds off a smaller daughter cell; hence the colloquial name of S. 
cerevisiae is budding yeast. 
Each phase of the cell cycle is associated with specific cyclins, e.g. Cln 
cyclins during G1 and Clb cyclins during the S, G2 and M phases. 
Cdc28p/Cdk1p, which is the major cyclin dependent protein kinase (CDK) in 
yeast, performs phase-specific signalling during the cell cycle by associating 
with the different cyclins. Another CDK is Pho85p, which has its own set of 
cyclins, and is involved in the response to different external phosphate levels. 
The ordered progression of the cell cycle is subject to several checkpoints 
when the cell cycle can be halted to ensure coordination of different processes 
(Pringle et al., 1997). 
2.1 START of the cell cycle and TORC1 and PKA signalling 
The metabolic regulation of the cell cycle takes place in the G1 phase. During 
G1 S. cerevisiae decides if conditions are favourable enough to commit the cell 
to progress through the next cell cycle. If conditions are favourable, the 
association of the early cyclin Cln3p with Cdc28p, and the resulting activation 
of the CDK, induces the START condition in which over 200 genes are 
upregulated, including the genes coding for the next set of cyclins, Cln1p and 
Cln2p. Cln3p is regulated at the transcriptional level by glucose and acetyl-
CoA, and the translation of Cln3p is regulated by the TOR and RAS-cAMP-
PKA nutrient sensing pathways (Shi and Tu, 2013). 
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S. cerevisiae has two RAS proteins, Ras1p and Ras2p. The N-terminal of 
the RAS-GEF Cdc25p is involved in glucose sensing through mechanisms that 
are still poorly understood; Ras1p and Ras2p have been shown to be activated 
by intracellular acidification independent of glucose and Cdc25p. Cdc25p or 
intracellular acidification or both propagates a signal through the Cdc25p-
RAS-cAMP-PKA pathway. Moreover, Cdc25p is thought to be regulated by a 
negative feedback involving protein kinase A (PKA) phosphorylation, which 
could prevent overproduction of cAMP during growth on high glucose 
(Colombo et al., 1998; Gross et al., 1999).  
Hypothetically, since cAMP is produced from ATP, the energy status of the 
cell (reflected by the ATP concentration) could synergistically interact with 
both intracellular acidification and glucose to determine the subsequent activity 
of PKA. 
Furthermore, the G-protein Gpa2p together with the G-protein coupled 
receptor Gpr1p can produce cAMP and activate PKA via a separate glucose 
induced signalling pathway (Colombo et al., 1998; Kraakman et al., 1999; 
Wang et al., 2004). 
TORC1 is a signalling complex containing either of the redundant Tor1p or 
Tor2p protein kinases. TORC1 senses the availability and quality of nutrients 
including carbon and nitrogen in the form of amino acids and ammonium. 
TORC1 phosphorylates and activates the protein kinase B homologue Sch9p if 
conditions are favourable for proliferation. There is also another complex 
TORC2, which only contains the Tor2p kinase, and differs from TORC1 in its 
upstream effectors and downstream targets. There are indications that TORC2 
is activated by ribosomal association, and inhibited by environmental stress 
(Loewith and Hall, 2011; Wanke et al., 2008). TORC2 is involved in 
regulating actin organization, maintaining cell wall integrity, and regulating 
ceramide biosynthesis via phosphorylation of the downstream targets Slm1p, 
Slm2p, and Ypk2p; Ypk2p being the major target (Liao and Chen, 2012). 
TORC2 has furthermore been shown to positively regulate the activity of the 
pentose phosphate pathway, which generates the nucleotide precursor ribose-5-
phosphate (Kliegman et al., 2013). 
2.2 The G0 phase and the diauxic shift 
S. cerevisiae cells can also exit from G1 into a stationary G0 phase. This 
eventually happens when yeast cells run out of nutrients, but stationary phase is 
preceded by the diauxic shift, during which S. cerevisiae switches from 
fermentation to respiration. The AMPK homologue Snf1p is important for the 
regulation of transcription during entry into the non-fermentative post diauxic 
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shift growth phase. When the energy status of the cell goes down, the 
concentration of ADP rises. Snf1p is activated due to this rise in ADP 
concentration. Activated Snf1p phosphorylates and activates several 
transcription factors, but deactivates both the Sch9p protein kinase mentioned 
above, and the transcriptional repressor Mig1p. Deactivation of Mig1p by 
Snf1p-dependent phosphorylation allows the expression of genes responsible 
for the utilization of non-fermentable and other non-preferred carbon sources, 
such as galactose (Celenza and Carlson, 1984; Lu et al., 2011; Mayer et al., 
2011; Nehlin and Ronne, 1990). 
In a parallel pathway the protein kinase Rim15p integrates signals from 
several nutrient sensing pathways and controls entry into stationary phase. 
Either loss of nitrogen- or carbon-dependent TORC1-Sch9p signalling or loss 
of phosphate-dependent Pho80p-Pho85p signalling causes dephosphorylation 
and nuclear import of Rim15p. A simultaneous loss RAS-cAMP-PKA 
signalling due to lack of fermentable carbon sources releases the inhibition of 
Rim15p protein kinase activity and promotes entry into G0 (Pedruzzi et al., 
2003; Wanke et al., 2008, 2005).  
2.2.1 The Gis1p and Rph1p transcriptions factors 
Genome wide transcription profiling indicates that the effect of Rim15p on 
gene expression during the diauxic shift is almost entirely mediated by the 
transcription factors Msn2p, Msn4p, Gis1p and Rph1. Msn2p and Msn4p are 
STRE-element binding transcription factors, which control transcription in 
response to a variety of stress conditions. Gis1p is a Post Diauxic Shift, PDS-
element binding transcription factor, which also binds to the STRE element 
(Cameroni et al., 2004; Swinnen et al., 2006). However, it has been reported 
that Rim15p does not directly phosphorylate Gis1p in vitro, but only Msn2p, 
which suggest that a unknown protein kinase might convey the signal from 
Rim15p to Gis1p (Lee et al., 2013). 
Gis1p also has a homologue called Rph1p. Both are C2H2 zinc finger 
proteins, and are involved in growth phase dependent gene regulation. In the 
log phase Gis1p and Rph1p mainly act as redundant repressors of gene 
expression. In contrast to the log phase, Rph1p and Gis1p act as both activators 
and repressors, and target different sets of genes in the PDS (Orzechowski 
Westholm et al., 2012). Similar to Gis1p, Rph1p also gets phosphorylated after 
treatment with the TORC1 inhibitor rapamycin (Huber et al., 2009). Taken 
together, this suggests that also Rph1p is a downstream effector of Rim15p. 
Sch9p inactivation dependent activation of Gis1p is also DNA-protective by 
causing downregulation of  Rev1p, which is a component of the error prone 
translesion DNA polymerase Zeta complex, and by causing upregulation of 
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Sod2p, which prevents superoxide dependent DNA oxidation (Fabrizio et al., 
2003; Madia et al., 2009). 
2.2.2 Rph1p and H3K36 histone methylation 
Rph1p and Gis1p both have JmjN and JmjC domains (Balciunas and Ronne, 
2000). The JmjC domain, which is found in many eukaryotic proteins, has 
histone demethylase activity. This activity is present in Rph1p, but the JmjC 
domain of Gis1p seems to lack histone demethylase activity, since it is mutated 
in a key amino acid residue involved in co-factor coordination. Rph1p 
demethylates the tri- and di-methylated form of the lysine found at position 36 
in histone H3, called H3K36 (Klose et al., 2007, 2006). 
The H3K36 residue is methylated by the H3K36 methyltransferase Set2p 
during transcription. This in turn recruits the histone deacetylase complex 
Rpd3S, which represses spurious ORF-internal transcription by chromatin 
deacetylation (Carrozza et al., 2005; Drouin et al., 2010; Krogan et al., 2003). 
Given the fact that the methylation state of H3K36 indirectly modifies the 
accessibility of the chromatin for transcription, one might expect transcription 
regulation by Rph1p to be dependent on its H3K36 demethylase activity. 
However, we found in publication II that the histone demethylase activity of 
Rph1p is largely dispensable for transcriptional regulation by Rph1p.  
In a human cell line and in the fission yeast Schizosaccharomyces pombe, 
the Set2p dependent methylation of H3K36, which is removed by Rph1p, is 
facilitating DNA-repair by the non-homologous end joining pathway (NHEJ) 
(Fnu et al., 2010; Pai et al., 2014). NHEJ is an error prone repair mechanism, 
and hence mutagenic, for double strand breaks in DNA. NHEJ is described in 
more detail in chapter 3.2.4 in this thesis. 
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3 Cell cycle arrest and DNA damage 
3.1 DNA damage and DNA breaks 
Common single strand lesions in DNA during normal growth are caused by the 
processing of DNA bases that have been damage by oxidation. Oxidative 
damage turns guanosine into 8-oxoguanosine, and thymidine into thymidine 
glycol. Another major DNA lesion is the spontaneous deamination of 
deoxycytidine resulting in a deoxyuridine. The removal and repair of damaged 
bases results in intermediate apyrimidinic or apurinic sites (AP-sites), and 
single strand breaks (SSB) via the base excision repair (BER) pathway 
described below. If two SSBs happen in close proximity, or the replication fork 
stalls at a SSB then the DNA molecule can break in two parts, with either 3’ or 
5’ overhangs at the ends. This type of lesion is called a double strand break 
(DSB). Virtually all DSBs happen during the S phase. From the estimated rate 
of production of single strand lesions under normal conditions, 1% of the SSBs 
are estimated to be converted into DSBs. The estimated rate of DSB formation 
is around one DSB per 108 base pairs per cell cycle in a range of organisms. 
This is in line with the finding that 22% of all S. cerevisiae cells in S phase has 
Rad52p foci indicative of active DSB repair (Collura et al., 2012; Impellizzeri 
et al., 1991; Lisby et al., 2001; Vilenchik and Knudson, 2003). 
DSBs in S. cerevisiae can be repaired more or less accurately by three 
mechanisms. DSBs with short overhangs of up to 10 bases tend to be religated 
with or without errors by non-homologous end joining (NHEJ). In spite of its 
name NHEJ can efficiently religate compatible overhangs without loss of 
bases, but bases may also be lost in the process. DSBs with longer overhangs 
tend to be repaired precisely and error free by a homologous recombination 
repair mechanism (HRR). Longer non-compatible overhangs, which could be 
generated by exonucleases, are repaired by a mechanism independent of NHEJ 
and HRR, the microhomology mediated end joining (MMEJ) which is error 
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prone and causes deletions (Daley and Wilson, 2005). The frequency of SSBs 
and DBSs can be increased by growth in the presence of 5-fluorouracil, see 
chapter 5.6.2 in this thesis. 
  
Figure 1. Simplified outline of the major DNA repair pathways in yeast, from DSB to DDR 
signalling and cell cycle regulated DNA repair. Damaged DNA molecules with DSBs at the lower 
ends, and with different bound repair complexes are shown to the left in the figure. 
3.2 DNA repair mechanisms and DNA damage signalling 
The DNA damage response (DDR) has a central signal protein Rad53p, which 
becomes phosphorylated and activated after DNA damage. The Chk1p protein 
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is another mediator of the DDR. DNA damage activation of Chk1p is mediated 
by Rad9p, and is enhanced by phosphorylation of Rad9p by Cdc28p in 
association with B-type cyclins during the S and G2 phases. This makes it 
possible to modulate DDR in coordination with the cell cycle (Abreu et al., 
2013). Rad53p is also activated at stalled replication forks in a Mec1p and 
Mrc1p dependent manner. Stalled replication can indicate DNA-lesions, or 
lack of replication factors  (Osborn and Elledge, 2003). Rad53p phosphorylates 
the Dun1p kinase, which subsequently phosphorylates the ribonucleotide 
reductase (RNR) inhibitor Sml1p. The phosphorylation of Sml1p promotes its 
degradation and activation of RNR. RNR is the rate limiting step in production 
of dNTPs from NTP. The increased synthesis of dNTPs by activated RNR can 
help recover from DNA damage and stalled replication (Chen et al., 2007; 
Zhao and Rothstein, 2002). 
The main initiator of Rad53p DDR signalling is DSBs, but nucleotide 
excision repair (NER) can also activate the DDR signalling. Initially Tel1p is 
recruited to the ends of the DSB by the Mre11p MRX-complex. Tel1p then 
activates Rad53p DDR signalling via activation of Rad9p (Clerici et al., 2014; 
Corda et al., 2005; Schwartz et al., 2002). 
As it is involved in all major DSB repair pathways, the Mre11p MRX-
complex has several important features: dsDNA 3’-5’ exonuclease activity, 3’ 
overhang endonuclease activity, and 5’-3’ stepwise dsDNA exonuclease 
activity (Trujillo and Sung, 2001; Zhu et al., 2008). See Figure 1 for a 
simplified outline of the major DNA repair pathways in yeast, from DNA 
damage to DDR signalling and cell cycle regulated DNA repair. 
3.2.1 Base excision repair 
Non-canonical bases in DNA can be recognized and removed by enzymes 
called DNA glycosylases; this generates an apurinic or apyrimidinic site (an 
AP-site), i.e. a DNA-bound deoxyribose-5’-phosphate. Examples of DNA-
glycosylases in S. cerevisiae are Ung1p, which recognizes uracil, Ogg1p, 
which recognizes 8-oxyguanine, Ntg1p and Ntg2p, which recognize oxidized 
pyrimidines such as thymine glycol, and Mag1p, which recognizes 3-
methyladenine, e.g. adenine alkylated with methylmethanesulfonate (MMS). 
After the removal of the damaged nucleobase, the repair can proceed either 
through single nucleotide base excision repair (SN-BER), or through long 
patch base excision repair (LP-BER). 
In SN-BER, the Ogg1p, Ntg1p or Ntg2p proteins, which also have AP-site 
lyase activity, cleave the 3’ phosphodiester bond of the AP-site. The AP-site 
endonuclease Apn1p then cleaves the 5’ phosphodiester bond leaving a single 
nucleotide gap. The gap is filled by a DNA-polymerase, possibly Pol4p (since 
23 
Pol4p has been shown to be of importance for MMS tolerance). The resulting 
DNA-strand nick is then sealed by the DNA-ligase Cdc9p or Dnl4p. 
Alternatively, SN-BER starts with cleavage of the AP-site 5’ phosphodiester 
bond by the AP-site endonuclease Apn1p. The lyase activity of Trf4p then 
cleaves the AP-site 3’ phosphodiester bond leaving a single nucleotide gap, 
which is repaired by Pol4p and Cdc9p or Dnl4p, as described above (Chen et 
al., 1989; Gellon et al., 2008; Meadows et al., 2003; Sterling and Sweasy, 
2006). 
LP-BER starts with cleavage of the AP-site 5’ phosphodiester bond by the 
AP-site endonuclease Apn1p. DNA-polymerase epsilon or delta then repairs 
the lesion by strand displacement. This process is especially useful if the 
deoxyribose is damaged, which would inhibit the subsequent Trf4p lyase 
activity in SN-BER. The 5´ flap endonuclease Rad27p then cleaves the 
displaced strand containing the AP-site in its 5’ end. The resulting DNA-strand 
nick can then be sealed by the DNA ligase Cdc9p or Dnl4p (Blank et al., 1994; 
Wang et al., 1993; Wu and Wang, 1999) 
The inactivation of the AP-site endonucleases Apn1p and Apn2p by 
knocking out of the corresponding genes results in constant DDR signalling via 
phosphorylation of Rad53p, and causes a delay in the progression of the cell 
cycle at the G2/M transition. This indicates that a malfunctional BER results in 
genetic instability since Rad53p DDR signalling is activated by the major DNA 
lesions: DSB, stalled replication, or resected nucleotide excision repair (NER) 
repair (see below). Phenotyping of strains mutated in other DNA repair 
pathways in combination with a disabled BER suggest that NER, HRR, and 
mutagenic translesion bypass synthesis (TLS) are all involved in compensating 
for loss of BER (Collura et al., 2012; Swanson et al., 1999). 
3.2.2 Nucleotide excision repair 
The NER pathway repairs a wide range of DNA lesions: intrastrand crosslinks, 
bulky nucleobase adducts, and other helix distorting lesions. NER is also 
involved in repair of interstrand crosslinks. NER relies on two mechanisms to 
localize the lesion. One mechanism is coupled to transcription and is initiated 
when RNA polymerase II encounters a lesion on the transcribed strand; this 
pathway is called transcription coupled repair (TCR). The other pathway relies 
on continuous surveillance of the helix structure; this pathway is called global 
genomic repair (GGR). When a lesion has been found, the NER complex 
excises a stretch of around 25 nucleotides centred at the lesion. The gap is 
refilled by DNA polymerase delta or epsilon, and the last nick in the DNA is 
sealed by Cdc9p (Enoiu et al., 2012; Tatum and Li, 2011). 
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NER repair can in turn induce Rad53p-dependent DDR signalling. Either 
lack of replication factors, or the presence of another lesion on the template 
strand may cause the DNA polymerase to stall during the refilling of the gap. 
This leaves an exposed 5’ end that is substrate for the 5’-3’ exonuclease 
Exo1p. Exo1p then generates a long stretch of SSDNA that induces the Rad53p 
DDR signal as described below under homologous recombination repair 
(HRR) (Giannattasio et al., 2010). 
3.2.3 Homologous recombination repair 
HRR is a repair mechanism with high fidelity that relies on a homologous 
DNA template, either a sister chromatid or a homologous chromosome in 
diploid cells. The 3’ DNA strands of the two broken ends invade the 
homologous DNA by strand exchange and are then elongated using the 
homologous DNA as a template. Depending on how the repair process resolves 
it may also result in recombination between the two DNA helices. 
The initial processing of a DSB is influenced by the cell cycle. The Sae2p 
protein is phosphorylated and activated by Cdc28p in the S and G2 phases. 
Activated Sae2p in association with the Mre11p-complex processes the DSB 
end to generate a short 3’ overhang. This primes the processed DSB end for 
further 5’-3’ exonuclease processing by either Exo1p, or the Sgs1p helicase 
complex and the Dna2p exonuclease; this 5’-3’ exonuclease processing extends 
3’ ssDNA.  Moreover, the initial processing of the DSB reduces its affinity for 
the Ku-complex, which is essential for the non-homologous end joining repair, 
NHEJ, thus blocking the latter. Furthermore, the Dna2p is also activated by 
Cdc28p during the S and G2 phases (Chen et al., 2011; Foster et al., 2011; 
Huertas et al., 2008; Mimitou and Symington, 2008; Zhu et al., 2008). 
A model for DDR activation ssDNA has been proposed. Replication protein 
A (RPA) first binds to the protruding ssDNA. The Mec1p/Dcd2p heterodimer 
in association with the Rad24p-RFG-Clamploader then binds to the RPA 
molecules and loads the Rad17p-Clamp. The association between 
Mec1p/Dcd2p, RPA, and the Rad17p-Clamp activates the kinase activity of 
Mec1p. Mec1p then phosphorylates and activates Rad9p and the DDR 
signalling protein Rad53p. Rad9p further induces the autophosphorylation and 
activation of Rad53p, which in turn activates the Rad55p/Rad57p complex (see 
below). Rad9p and Rad53p also provide a negative feedback by inhibiting 
Exo1p, which prevents further generation of SSDNA (Clerici et al., 2014; 
Gilbert et al., 2001; Jia et al., 2004; Majka et al., 2006; Schwartz et al., 2002; 
Vialard et al., 1998). 
The RecA homologue Rad51p is an ssDNA binding protein that facilitates 
homology search by DNA strand exchange between homologous DNA helices, 
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something which is strictly required for HRR. Rad52p and the Rad55p/Rad57p 
complex facilitate the loading of Rad51p onto ssDNA while displacing RPA. 
Rad53p, the DDR signalling protein, activates the Rad55p/Rad57p complex, 
and Mec1p bound to RPA sitting on ssDNA is thought to activate Rad51p 
(Flott et al., 2011; Herzberg et al., 2006; Miyazaki et al., 2004; Sugiyama and 
Kowalczykowski, 2002). 
3.2.4 Non-homologous end joining 
The efficiency of the NHEJ pathway is dependent on it being error-prone. 
NHEJ either trims or fills in the DSB DNA overhangs and then religates them, 
which often result in point mutations and loss of bases. Several protein 
complexes are engaged in NHEJ. The Ku complex preferentially binds, 
encircles, and stabilizes DSBs with short overhangs or blunt ends (Foster et al., 
2011). The Ku complex then recruits the Mre11p-MRX nuclease complex, the 
Dnl4p/Lif1p/Nej1p DNA ligase complex, and the mismatch tolerant Pol4p 
DNA polymerase  (Pardo et al., 2006; Zhang et al., 2007).  
In the S and G2 phases Cdc28p phosphorylates Lif1p, which makes the 
NHEJ more efficient in performing mutagenic religations. This mode of repair 
is called imprecise NHEJ (Matsuzaki et al., 2012). 
In a human cell line and in the fission yeast S. pombe Set2p dependent 
methylation of H3K36 has been shown to facilitate DNA repair by NHEJ 
pathway (Fnu et al., 2010; Pai et al., 2014). The H3K36 methylation is 
removed by the histone demethylase Rph1p in S. cerevisiae. The role of the 
histone demethylase enzymatic activity of Rph1p in gene regulation was 
investigated in publication II in this thesis. 
3.2.5 Microhomology mediated end joining, MMEJ 
The MMEJ pathway is independent of the Ku complex of the NHEJ pathway 
and the Rad52p protein of the HRR pathway, and is therefore considered a 
separate mode of DSB repair. MMEJ is dependent on the Mre11-MRX 
nuclease complex, the Rad1p/Rad10p 3’ flap nuclease complex, and the Dnl4p 
DNA ligase. MMEJ can ligate non-compatible ends by processing them until 
an imperfect microhomology of about 8-10 bases is found. Dnl4p then ligates 
the DSB with the result of a deletion spanning the region between the two 
microhomologies (Ma et al., 2003). 
3.3 DNA and RNA damage signalling and cell cycle arrest 
Activation of the DDR pathway causes a temporary cell cycle arrest in S. 
cerevisiae in order to give the cell time to repair the lesion. However, even if 
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DSBs persist the cell eventually adapts after about 8-15 hours and attempts to 
progress though the cell cycle regardless of the unrepaired DSBs. The 
adaptation correlates with a reduction in activity and phosphorylation of Chk1p 
and Rad53p, i.e. with deactivation of both branches of the DDR signalling 
(Vidanes et al., 2010). Shown in Figure 2 is a simplified outline of the DDR 
signalling pathways leading to cell cycle arrest. 
 
Figure 2. Simplified outline of the DDR signalling pathways leading to cell cycle arrest. Dashed 
arrows indicate proposed interactions that are still poorly characterized.  
 
3.3.1 G1 arrest 
G1 arrest from DDR signalling 
DNA damage by MMS during the G1 phase causes an immediate drop in the 
late G1 cyclins Cln1p and Cln2p, which prevents progression of the cell cycle; 
this is an uncharacterized pathway which appears to be independent of DDR 
signalling via Rad53p. However, during DDR signalling, activated Rad53p 
phosphorylates Swi6p and thereby inhibits the Swi4p/Swi6p transcriptional 
activator complex SBF. This also extends the G1 phase since SBF positively 
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regulates the same late G1 cyclins Cln1p and Cln2p, which are necessary for 
progression through START into the S phase of the cell cycle (Sidorova and 
Breeden, 1997). 
G1 arrest from intranuclear accumulation of immature tRNA 
tRNA biogenesis is a complex process. The tRNA genes are transcribed by 
RNA polymerase III. About 20% (59 of 286) of the tRNA genes have introns, 
and S. cerevisiae tRNAs undergo 25 different modifications of nucleobases and 
ribose, but not all modifications are found in each tRNA. The modifying 
enzymes act both inside and outside of the nucleus. Before nuclear export the 
3’ and 5’ ends of the pre-tRNA are processed. Both spliced and unspliced 
tRNAs are exported via nuclear pores in association with the Ran1p GTPase 
and exportins. Intron-containing tRNAs are spliced in the cytoplasm. tRNAs 
are then reimported into the nucleus constitutively and at least one spliced 
tRNA, tRNA(Phe), is then further modified. Los1p is the main exportin for 
intron-containing tRNAs, and Msn5p is the main exportin for spliced and 
intron-less tRNAs. However, since the double knockout los1 msn5 is viable, 
there must also exist other means to export tRNA out of the nucleus. It is 
thought that intranuclear aminoacylation and nuclear-cytoplasmic tRNA 
cycling are parts of a tRNA surveillance system that prevents aberrant tRNAs 
from accumulating in the cytoplasm and interfere with translation (Chan and 
Lowe, 2009; Hopper, 2013; Kramer and Hopper, 2013; Murthi et al., 2010; 
Ohira and Suzuki, 2011). Accordingly, nuclear export of tRNAs is dependent 
on a mature structure of the tRNA backbone including post-transcriptional 
modifications e.g. pseudouridylation by Pus1p (Großhans et al., 2001; Hopper, 
2013).  
Retention of immature tRNAs in the nucleus induces the expression of the 
Gcn4p transcription factor independently of Gcn2p, which induces 
transcription of Gcn4p in response to amino acid starvation. The retention of 
immature tRNA in the nucleus can also be an active process. DDR signalling 
via Rad53p induces relocalization of the tRNA exportin Los1p to the 
cytoplasm. Unspliced tRNAs then accumulate in the nucleus and cause 
activation of Gcn4p. Gcn4p in turn reduces the accumulation of the late G1 
cyclin Cln2p and thereby delays the progression of the cell cycle into S phase 
(Ghavidel et al., 2007; Qiu et al., 2000; Vazquez de Aldana et al., 1994, p. 4). 
3.3.2 S-phase arrest 
The Cdc7p protein kinase associates with its regulatory subunit Dbf4p, which 
accumulates at the G1 to S transition. The Dbf4p-Cdc7p is required for both 
early and late S-phase replication firing (i.e. start of DNA replication).  Dbf4p-
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Cdc7p associates with origin of replication complexes (ORCs) and 
phosphorylates the proteins Mcm2p and Mcm4p. The DDR signalling protein 
Rad53p inhibits this process by phosphorylating Dbf4p. This prevents 
association of the Dbf4p-Cdc7p with ORCs, which results in an inhibition of 
late origin firing, and induction of an S-phase arrest (Duncker et al., 2002; Lei 
et al., 1997; Sheu and Stillman, 2006). 
Finally, it should be noted that replication fork progression also slows down 
in response to DNA damage, but this response is independent of Rad53p 
(Tercero and Diffley, 2001). 
3.3.3 G2/M arrest 
Mitotic entry is driven by Cdc28p activation, and prevented by Swe1p-
dependent phosphorylation of Cdc28p. The Swe1p-dependent phosphorylation 
inhibits the Clb2p-Cdc28p kinase, thereby preventing phosphorylation of 
targets critical for mitotic entry (Hu and Aparicio, 2005; Rossio and Yoshida, 
2011). 
Prophase chromosome condensation is mediated by the Smc2p-Smc4p 
condensin complex. Cdc28p homologues in vertebrates, S. pombe and Xenopus 
induce chromosome condensation, in S. pombe by phosphorylation of the 
condensin subunit Smc4p, but it is still unknown if Clb2-Cdc28p activates 
condensin in S. cerevisiae. Finally, Cdc28p signalling is also of importance for 
the attachment of microtubules to kinetochores, which is needed for chromatid 
separation (Enserink and Kolodner, 2010; Li and Elledge, 2003). 
Inhibition of anaphase 
The late B cyclin Clb2p in association with Cdc28p phosphorylates the DDR 
signalling protein kinase Rad9p. This primes Rad9p for phosphorylation and 
activation of the downstream effector Chk1p (Abreu et al., 2013). Chk1p in 
turn phosphorylates the securin Pds1p, which prevents its degradation; 
degradation of Pds1p would otherwise have been be induced by the anaphase 
promoting complex. Phosphorylated Pds1p continue to inhibit the separase 
Esp1p, which is responsible for loss of cohesion between sister chromatids 
during progression from metaphase to anaphase, thereby preventing 
progression into the anaphase (Ciosk et al., 1998; Wang et al., 2001). 
Inhibition of mitotic exit 
Rad53p also inhibits the polo kinase Cdc5p, which results in 
hypophosphorylation and activation of the GAP Bfa1p-Bub2p. Bfa1p-Bub2p 
inhibits the GTPase Tem1p, which would otherwise promote the initiation of 
mitotic exit by the mitotic exit network (MEN) which is responsible for the 
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completion of mitosis. However, this checkpoint seems to respond only to 
DNA damage at the telomeres, and not to DSBs in general (Valerio-Santiago et 
al., 2013). Inhibition of the polo kinase Cdc5p by Rad53p also indirectly 
prevents spindle elongation and chromosome segregation during anaphase B 
(Zhang et al., 2009). 
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4 Cancer 
The survival of a multicellular organism requires that all cells, both germ line 
and somatic, stay in line and act according to the plan for the common good. 
Individualistic endeavour is strongly discouraged; upon tendencies to deflect, 
the cell is simply ordered to commit suicide, which it does without hesitation. 
However, the plan is not written in stone, but with deoxynucleotides, and 
perhaps the plan was not perfectly waterproof to begin with. Over time and cell 
divisions the inherent imperfectnesses of DNA replication and DNA repair 
starts to obscure the plan, until a day comes when the cell discovers that it has 
a brand new plan: I am. 
In reality, cells in multicellular organisms need several transformations to 
gradually develop into a malignant neoplasm, i.e. a cancer. Malignancy means 
that the tumour spreads by dislodging tumour cells into blood vessels, cells 
which act as seeds for new tumours throughout the body. These new tumours 
are called metastases.  
When the cancer has metastasized in its host, what eventually causes death 
can be direct organ disruption from tumour growth, but is often (around 30% 
of deaths) a metabolic state called cachexia. Cachexia is a catabolic state in 
which body tissue is continuously wasted in spite of adequate nutrient intake.  
Cachexia is caused by persistent release of cytokines and other factors not only 
from the tumour but mainly from the host (Onesti and Guttridge, 2014). Death 
can also be caused by abnormal inflammation that induces the multiple organ 
dysfunction syndrome, MODS (M E McFadden, 1992). 
Cancer-causative mutations typically involve tumour suppressor genes or 
oncogenes. Both alleles of a tumour suppressor gene generally need to be 
deactivated for loss of an anticancer phenotype whereas a gain of function 
mutation in one allele of an oncogene is enough for a pro cancer phenotype. 
The review Hallmarks of Cancer (Hanahan and Weinberg, 2011) stresses that 
there is an underlying phenotype of genetic instability and increased mutation 
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rate that enables cells to acquire the other hallmarks of cancer; hallmarks are 
characteristics which are needed for transformation to malignancy.  In contrast, 
others emphasize the role of selection and clonal expansion as being more 
important. In these models, a normal mutation rate is considered high enough 
to cause cancer. However, all models agree that genetic instability is important 
in a subset of cancers, and that an increased mutation rate generally would 
transform healthy tissue into a cancer faster. They further point to the fact that 
there are solid tumours with no apparent form of genomic instability and that 
most haematological malignancies do not show clear signs of genomic 
instability (Abdel-Rahman, 2008; Tomlinson et al., 2002). 
Hanahan and Weinberg (2011) also emphasized the importance of tumour 
induced inflammation as a malignancy enabling characteristic. The 
inflammation, which is caused mainly by innate immune system cells inside 
the tumour, provides essential factors fostering tumourgenesis. They also 
emphasize the important role of the stroma for sustaining tumourgenesis. The 
stroma is composed of recruited and subverted healthy non-immune system 
cells inside the tumour, and provides signalling feedback and structural and 
vascular support. 
To transform into a malignant neoplasm cells need to acquire several 
hallmarks according to Hanahan and Weinberg (2011): 
1. The cells need to sustain proliferative signalling, either by becoming 
truly self-sustaining for growth signals, by over-responding to growth 
signals from its environment, or by making surrounding cells provide 
growth signals via feed-back regulation. 
2. The cells need to overcome both intracellular and extracellular 
inhibitory signals and resist induced cell death, i.e. apoptosis. The 
evasion from destruction by the immune system seems to be important, 
but Hanahan and Weinberg argue that it remains to be shown that anti-
tumour immunity is a significant barrier to tumour formation.   
3. The uninhibited and constantly proliferating cell will eventually have to 
develop replicative immortality, in order to avoid senescence. 
4. The growing tumour needs angiogenesis, the creation of new blood 
vessels, for supporting its expanding cell mass with nutrients. 
5. In order to metastasize, tumour cells also need to develop traits to 
remodel and degrade their surrounding extracellular matrix, loose there 
attachment to neighbour cells, and become more migratory. 
6. Reprogramming of the energy metabolism is very common in cancers. 
The Warburg effect, in which cells ferment glucose to lactate even in 
the presence of oxygen, has been suggested as a mean to generate 
NADPH and to divert glycolytic and citric acid cycle intermediates into 
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precursors for biosynthetic pathways (Vander Heiden et al., 2009). In 
agreement with this, a broad spectrum of tumours have been found to 
not only upregulate glycolytic enzymes, but also enzymes in the de 
novo synthesis pathways of nucleotides (Weber, 2001). It should be 
noted, however, that increased fermentation in tumour tissue can also 
result from lack of oxygen due to poor vascularization. 
4.1 Saccharomyces cerevisiae as a model in cancer research 
The yeast S. cerevisiae cannot be considered multicellular, though it has the 
capacity to form pseudohyphae, and a unicellular organism cannot by 
definition develop cancer. However, to the extent that the underlying 
mechanisms are conserved between yeast and human cells, research in S. 
cerevisiae can contribute to the understanding of several important aspects of 
human cancers e.g. basic metabolism, DNA-damage and repair, and 
detoxification and resistance to cytotoxic drugs. 
Even though the same signalling pathways frequently are found in yeast and 
human cells, there can be noteworthy differences in how they function. One 
example involves the notorious oncogene RAS: RAS driven PKA signalling is 
pro-proliferative in S. cerevisiae, whereas in human cancers trimeric G-protein 
driven PKA signalling may instead dampen proliferative signals. PKA 
signalling in these human cancers acts by inhibiting the aberrant constitutive 
binding between human RAS carrying oncogenic mutations and its 
downstream effectors B-Raf and C-Raf. This aberrant binding is responsible 
for persistent growth signalling in some cancers (Li et al., 2013). See also 




5 Nucleotide metabolism 
Nucleobases are nitrogen rich heterocyclic compounds which can be 
components of nucleotides. The canonical nucleobases are uracil, cytosine, 
thymine, adenine and guanine. Nucleobases bound to the 1’ position of a 
deoxyribose or ribose sugar form compounds called deoxyribonucleosides and 
ribonucleosides respectively. The prefix/infix ribo is often left out. Nucleotides 
are composed of nucleosides with a mono, di, or tri phosphate linked to the 5’ 
position of the ribose, see Table 1 for nucleobases, nucleosides, and 
nucleotides of importance for this thesis. Ribonucleotide triphosphates are 
polymerized into RNA molecules and deoxyribonucleotide triphosphates into 
DNA molecules. The polymerization is coupled to the removal of a 
pyrophosphate from each nucleotide triphosphate. 
Table 1. Selected nucleobases, nucleosides and nucleotides of importance for this thesis. 
Nucleobase Nucleoside Nucleotide (triphosphate) 
Uracil, U Uridine,Urd UTP and dUTP 
5-Fluorouracil, 5-FU 5-Fluorouridine, 5-FUrd 5-FUTP 
Cytosine, C Cytidine, Cyd CTP 
Thymine, T Thymidine, dThd dTTP 
6-N-Hydroxylaminopurine, HAP  HAPTP 
Adenine, A Adenosine, Ado ATP 
Hypoxanthine, I Inosine, Ino ITP 
Guanine, G Guanosine, Guo GTP 
 
Nucleotides can be biosynthesized de novo from simpler precursors, or 
salvaged from nucleobases, which is called recycling or scavenging. 
Deoxyribonucleotides are synthesized in one step from the corresponding 
ribonucleotides. This enzymatic reaction, where the ribose of ribonucleotide-
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diphosphates is reduced, is catalyzed by the ribonucleotide reductase complex 
(RNR).  
The description of nucleotide metabolism in this thesis is mainly focused on 
the salvage and turn-over pathways, since the non-canonical nucleobases used 
in paper I and IV 5-fluorouracil (5-FU) and 6-N-hydroxylaminopurine (HAP) 
owe their toxicity to activation via the salvage pathways. The pyrimidine 
metabolism is summarized in Figure 3 and the purine metabolism in Figure 8. 
5.1 Nucleotides as energy carriers 
A nucleotide is more energy rich the more phosphates it has bound to the 
ribose at the 5’ position, the upper limit being a triphosphate. Cells synthesize 
nucleotide triphosphates in two steps. First, ATP is synthesized from ADP and 
inorganic phosphate through either fermentation or oxidative phosphorylation. 
Subsequently, GTP, CTP and UTP are produced from GDP, CDP, and UDP by 
transfer of one phosphate from ATP; the same process is also used to make 
deoxyribonucleotide triphosphates. This equilibration is catalyzed by the 
nucleoside-diphosphate kinase enzyme, which is called Ynk1p in S. cerevisiae 
(Jong and Ma, 1991). 
By coupling an energetically unfavorable reaction, such as polymerization 
of DNA, RNA, and polypeptides to the removal of phosphates from 
nucleotides the total reaction can become energetically favorable. Moreover, 
the coupling of nucleotide dephosphorylation makes possible otherwise 
energetically unfavorable biosynthetic reactions, e.g. carbamoyl-phosphate 
biosynthesis which is discussed in chapter 5.5.  
5.2 The role of nucleotides in signalling pathways 
Apart from their roles as energy carriers and precursors of RNA and DNA, 
nucleotides have additional roles in signalling pathways: ATP is commonly 
used for protein phosphorylation by protein kinases, such as PKA; GTP is used 
as a molecular switch by GTPases, such as RAS; and cAMP and ADP are used 
as second messenger signalling molecules. See chapter 2.1 and 2.2 in this 
thesis for more details. 
5.3 Nucleotide pool balance and regulation of de novo synthesis 
The balance between individual nucleotides within both the ribonucleotide and 
deoxyribonucleotide pool is important. Not only would depletion of one or 
more deoxyribonucleotides result in S-phase cell cycle arrest, but 
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deoxyribonucleotide imbalance alone, even without one or more limiting 
deoxyribonucleotides, results in mutagenesis due to incorporation of incorrect 
nucleotides during DNA synthesis (Kumar et al., 2010). 
5.3.1 Ribonucleotide pool balance and de novo synthesis 
S. cerevisiae uses several mechanisms to regulate the balance in the de novo 
synthesis of ribonucleotides. One notable strategy for balancing the 
ribonucleotide pool is to use one nucleotide as a co-reactant for the 
biosynthesis of another nucleotide. This increases the rate of synthesis of the 
former nucleotide when the latter nucleotide is abundant. 
The first enzyme in the de novo synthesis of pyrimidines, Ura2p, thus uses 
ATP, an end product of purine synthesis, as a co-reactant. Ura2p is also 
negatively feedback regulated by UTP, an end product in pyrimidine synthesis 
(Antonelli et al., 1998).  
On the contrary, the purine de novo synthesis is not thought to be regulated 
by the availability of pyrimidines; however, the first enzyme in this pathway, 
Ade4p, is feedback inhibited by the end product ATP (Rebora et al., 2001) . 
Inosine monophosphate, IMP, is a branch point intermediate in purine 
biosynthesis. One branch leads to the synthesis of ATP, the other branch to 
GTP. The first enzyme in the branch leading to ATP synthesis, Ade12p, uses 
GTP as a co-reactant (Lipps and Krauss, 1999). In contrast, the  enzymes 
Imd2p, Imd3p and Imd4p, which all catalyze the first step in the branch leading 
to GTP synthesis, are transcriptionally feedback inhibited by GDP (Escobar-
Henriques and Daignan-Fornier, 2001). The aminase reaction, catalyzed by 
Gua1p, that transforms XMP to GMP furthermore uses ATP as a co-activator 
(Saint-Marc and Daignan-Fornier, 2004). 
The ATP:GTP ratio is also balanced by the AMP-deaminase, Amd1p, 
which degrades AMP back to the branch-point intermediate IMP. Amd1p is 
allosterically activated by dATP and ATP, but inhibited by GTP. However, 
Amdp1 balancing is essential only when adenine is used as a source for purine 
biosynthesis, and de novo synthesis of purines is downregulated (Merkler and 
Schramm, 1990; Saint-Marc et al., 2009). 
CTP is synthesized from UTP by an amination reaction coupled to ATP 
dephosphorylation, which is catalyzed by the enzymes Ura7p and Ura8p. Both 
enzymes are negatively feedback regulated by CTP, but activated by GTP, 
which contributes to the CTP:GTP pool balance (Nadkarni et al., 1995; Yang 
et al., 1994). 
The de novo synthesis pathways of pyrimidines and purines are both feed-
forward activated by pathway intermediates. The purine intermediate SAICAR 
thus activates purine biosynthesis (Rebora et al., 2001), whereas the pyrimidine 
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intermediates dihydroorotic acid and orotic acid activate pyrimidine 
biosynthesis (Flynn and Reece, 1999). 
5.3.2 Deoxyribonucleotide pool balance 
All deoxyribonucleotides diphosphates except dTDP are directly synthesized 
from the corresponding ribonucleotide diphosphate by the ribonucleotide 
reductase complex (RNR). dTDP is instead made from dUDP which is 
synthesized from UDP by the RNR. dUDP is first phosphorylated to dUTP by 
Ynk1p, after which dUTP is dephosphorylated to dUMP by the dUTPase 
Dut1p. Thymidylate synthetase Cdc21p then catalyzes the methylation of 
dUMP to dTMP. dTMP is subsequently phosphorylated to dTDP by 
thymidylate kinase Cdc8p. The CDC8, CDC21 and RNR1 genes are 
upregulated during the G1 to S phase transition (Puig et al., 2013; White et al., 
1987).  
RNR catalyzes the conversion of ribonucleotides into deoxyribonucleotides, 
and thereby balances the deoxyribonucleotide pool. Balance means in vivo S. 
cerevisiae that the concentration of dTTP is 2-fold higher than that of dATP 
and dCTP, and 4-fold higher than that of dGTP. ATP allosterically activates 
RNR, and dATP allosterically inactivates RNR; consequently, RNR measures 
and balances the ratio between deoxyribonucleotides and ribonucleotides. RNR 
also balances the individual deoxyribonucleotides. dATP thus increases the 
specificity of RNR for CDP and UDP, dTTP increases the specificity of RNR 
for GDP, and dGTP increases the specificity of RNR for ADP (Kumar et al., 
2010). 
5.4 Pyrimidine salvage and turnover 
S. cerevisiae can utilize extracellular nucleotides through the Npp1, Npp2, and 
Pho5p mediated periplasmic degradation of nucleotides to phosphates and 
nucleosides (Kennedy et al., 2005).  
Cytidine is then taken up by the cytidine permease Fcy2p and uridine is 
taken up by the uridine permease Fui1p. However, nucleobases are preferred 
over nucleosides for nucleotide scavenging in S. cerevisiae, and pyrimidine 
nucleosides are also converted to uracil, in addition to direct nucleoside 
phosphorylation. When used as sources for pyrimidines, uridine, cytidine and 
deoxycytidine are first degraded to uracil and cytosine respectively, a reaction 
which is catalyzed by the uridine hydrolase Urh1p. Cytosine is then further 
deaminated to uracil by Fcy1p. Cytidine can also be deaminated to uridine by 
the Cdd1p deaminase, but the reaction is inefficient in vivo. In addition, the 
nucleosides cytidine, uridine and deoxycytidine can be phosphorylated by the 
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Urk1p kinase to CMP, UMP and dCMP respectively. Deoxyuridine cannot, 
however, be utilized by yeast (Kurtz et al., 1999, 2002; Wagner et al., 1998). 
It should be noted that Urh1p does not hydrolyze thymidine to thymine 
(Mitterbauer et al., 2002). Moreover, thymidine kinase is absent from yeast, 
and neither thymine nor thymidine can therefore be used as a substrate for 
synthesis of dTMP. dTMP can however be used directly to sustain DNA 
synthesis in some strains, but only with limited efficiency (Brendel and 
Haynes, 1973; Grivell and Jackson, 1968). 
Cytosine is taken up by the purine-cytosine transporter Fcy2p, and as 
mentioned above intracellular cytosine is always deaminated to uracil by the 
Fcy1p deaminase prior to conversion into pyrimidine nucleotides (Ferreira et 
al., 1997; Jund and Lacroute, 1970). Uracil is taken up by the uracil specific 
permease Fur4p (Jund et al., 1977). Uracil is then directly activated to UMP 
through a reaction with phosphoribosyl pyrophosphate (PRPP) which is 
catalyzed by Fur1p. FUR1 is moreover transcriptionally activated by its own 
substrate uracil (Kern et al., 1991). The FUR4 uracil permease is in contrast 
downregulated by uracil (Seron et al., 1999). 
Pyrimidine scavenging and salvage thus converges on UMP, which is 
converted to UDP by the UMP specific kinase Ura6p (Ma et al., 1990). No 
CMP or dCMP kinases have so far been found in S. cerevisiae. CMP could 
possibly be recycled via the Sdt1p nucleotidase, which can dephosphorylate 
CMP, UMP, 5-FUMP, and 5-FCMP, but not deoxyribonucleotides such as 
dCMP (Nakanishi and Sekimizu, 2002). dCMP can, however, be converted 
into dUMP by the Dcd1p deaminase. This dUMP is then further converted into 
dTMP by Cdc21p catalyzed methylation. Hence, dCMP would not be recycled, 
but converted into dTMP, through this pathway (McIntosh and Haynes, 1984). 
39 
 
Figure 3. Pyrimidine metabolism in S. cerevisiae with a focus on salvage and turnover. Thinner 
arrows mean that the reactions are known or expected to be of relatively minor importance. Most 
enzymatic reactions in the de novo synthesis of pyrimidines are not shown.  
5.5 Pyrimidine and arginine de novo synthesis 
The uridylate, cytidylate, and thymidylate nucleotides are all synthesized from 
a UMP intermediate. Interestingly, this de novo synthesis of UMP shares its 
first intermediate with the de novo synthesis of the amino acid arginine. The 
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first enzymatic step in the synthesis of either arginine or UMP is thus the 
condensation of carbonate, ammonium from glutamine, and phosphate from 
ATP, into carbamoyl phosphate (CP). The enzyme carrying out this reaction is 
called carbamoyl phosphate synthetase, often abbreviated CPSase, but 
sometimes CPase in yeast, and CPS in animals. Both yeast and animals have 
two different carbamoyl phosphate synthetases, one used in arginine 
biosynthesis and another one used in UMP biosynthesis.  
5.5.1 Carbamoyl phosphate synthetases of the pyrimidine biosynthetic 
pathway 
The most complex protein containing a carbamoyl phosphate synthetase 
domain is the multi-enzyme CAD, which is part of the UMP synthesis pathway 
in man. It contains two domains which together form carbamoyl phosphate 
synthetase 2 CPS2, but it also harbours domains that carry out the two 
subsequent steps in UMP synthesis: aspartate carbamoyl transferase (ATCase) 
and dihydroorotase (DHOase), producing carbamoyl aspartate (CAspate) and 
dihydroorotate (DHOate) respectively , see Figure 4, (Evans and Guy, 2004). 
 
Figure 4. Comparison of the first reactions in the de novo synthesis of UMP in human cells (top) 
and S. cerevisiae (bottom). Several reaction steps from DHOate to UMP are left out. 
Human CAD is found in the cytosol associated with mitochondria, but about a 
third of the proteins translocates to the nucleus during S-phase (Evans and 
Guy, 2004; Sigoillot et al., 2005). Its yeast orthologue Ura2p is also cytosolic 
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(Benoist et al., 2000) contradicting an earlier finding that it was associated with 
the nucleus (Nagy et al., 1989, 1982). 
A striking difference between human and yeast enzymes is the fact that the 
human CAD has an active dihydroorotase domain, whereas the yeast 
orthologue Ura2p only has a homologous but enzymatically dead domain 
(Souciet et al., 1989). As depicted in Figure 4, this synthesis step is instead 
mediated by the protein Ura4p in yeast (Lacroute, 1968). 
5.5.2 Carbamoyl phosphate synthetases of the arginine biosynthesis and the 
urea cycle 
In this pathway the differences between animals and fungi are more 
pronounced, both regarding localizations and functions of the enzymes, see 
Figure 5. 
 
Figure 5. Comparison of the first few reactions in the de novo synthesis of arginine, in human 
cells (top) and yeast (bottom). 
 
In yeast, the two unlinked genes CPA1 and CPA2 code for the two domains of 
this CPSase. Cpa1p is the smaller subunit, and contains the activity which 
removes ammonium from glutamine. The larger subunit Cpa2p catalyzes the 
condensation of carbonate, ammonium and phosphate into carbamoyl 
phosphate. 
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In the human orthologue of Cpa1/2p, CPS1, the two domains are present 
within one protein. However, the domain of CPS1 which is homologous to 
Cpa1p is no longer involved in deamination of glutamine, and CPS1 instead 
utilizes free ammonium cleaved from glutamine by the GLS2 glutaminase. It 
should be noted that the Cpa2p subunit of the yeast CPSase also can use free 
ammonium, but it is not as efficient a substrate as glutamine. The CPS1 
enzyme is allosterically activated by N-acetylglutamate (NAG) unlike the yeast 
CPSase. The yeast CPSase complex is instead allosterically activated by its 
natural substrate glutamine (Aledo et al., 2000; Funghini et al., 2003; Lacroute 
et al., 1965; Pierard and Schroter, 1978). 
A further difference between the two species is the fact that the yeast 
CPSase is located in the cytosol (Urrestarazu et al., 1977) whereas the human 
CPS1 protein is located in the mitochondrial matrix of hepatocytes, where it 
functions in the urea cycle (Funghini et al., 2003). 
 
5.5.3  Feedback inhibition of CPSase and cross-utilization of carbamoyl 
phosphate between arginine and UMP synthesis 
Interestingly, in isolated human hepatocytes, 66-90% of the de novo synthesis 
of pyrimidines uses CPS1 derived carbamoyl phosphate that is leaking from 
the mitochondria rather than CPS2 derived carbamoyl phosphate from the 
CAD multi-enzyme. This CPS1 dependent de novo synthesis of pyrimidines is 
not feedback inhibited by an expanded pyrimidine nucleotide pool, in contrast 
to the de novo synthesis that is dependent on CPS2. This cross-utilization of 
carbamoyl phosphate and lack of feedback regulation is most likely tissue 
specific since CPS1 is expressed only in the hepatocytes where it is involved in 
the urea cycle, and in the epithelial cells of the intestinal mucosa (Monks et al., 
1985; Wendler et al., 1983). 
In yeast, the carbamoyl phosphate produced by either Cpa1p/Cpa2p or 
Ura2p is freely available for arginine or pyrimidine synthesis, as both enzymes 
are cytosolic and a single pool of cytosolic carbamoyl phosphate therefore 
exists (Lacroute et al., 1965). 
UTP, which is a terminal product of pyrimidine synthesis, inhibits both the 
transcription of the URA2 gene as well as the CPSase and ATCase activities of 
the Ura2p enzyme. In human cells, it is only the CPSase activity of the 
orthologue CAD which is inhibited by UTP (Antonelli et al., 1998). 
The yeast CPSase subunit Cpa1p is similarly feedback inhibited by its end 
product arginine, at the translational level (Messenguy et al., 1983). In contrast, 
the human CPS1 protein is allosterically regulated by NAG, and the production 
of NAG by the enzyme N-acetylglutamate synthase is activated by glutamate 
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and arginine (Morizono et al., 2004). This makes sense since glutamate is the 
main carrier of the amine groups that are disposed of through the urea cycle 
whereas arginine is an intermediate in the urea cycle, and thus needed for its 
proper function. 
5.6 5-Fluorouracil 
5-FU was the first drug designed to specifically target cancer cells, and it has 
been used in the treatment of solid tumours for more than fifty years. It was 
rationally designed based upon the finding that rat hepatomas metabolized 
uracil faster than normal tissues. Heidelberger and colleagues therefore 
synthesized 5-FU in 1957 (Heidelberger et al., 1957), in an attempt to make a 
non-metabolizable uracil analogue. Its structure differs from uracil in that it has 
a fluorine atom substituting a hydrogen at the fifth position in the heterocyclic 
pyrimidine ring, the same position where thymine carries a methyl group, see 
Figure 6. This modification does not hinder base pairing with adenine and 5-
FU metabolites are therefore incorporated instead of uracil during DNA and 
RNA synthesis (Grem, 2000). 
 
Figure 6. Comparison of the structures of uracil, 5-fluorouracil and thymine. 
5.6.1 Metabolism of 5-FU 
5-FU and uracil are taken up into mammalian cells by the same facilitated 
transport system (Wohlhueter et al., 1980). Similarly, in S. cerevisiae, uracil 
and 5-FU are both taken up by the proton symporter Fur4p (Jund and Lacroute, 
1970). Inside the cell, 5-FU can then either be activated or degraded, see 
Figure 7. In S. cerevisiae, 5-FU is activated to 5-FUMP by the uracil 
phosphoribosyltransferase Fur1p (Kern et al., 1991). In mammalian cells, the 
same activation reaction is carried out by orotate phosphoribosyltransferase 
(OPRTase) but also through two other pathways (Fukushima et al., 1996). 
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In one of these pathways, uridine phosphorylase (UP) and uridine kinase 
(UK) produces 5-FUMP. In the other pathway, thymidine phosphorylase (TP) 
and thymidine kinase (TK) produces 5-FdUMP. This deoxyfluoropyrimidine 
can however also be generated by the conversion of 5-FUDP to 5-FdUDP, a 
reaction catalyzed by ribonucleotide reductase (RNR) in both S. cerevisiae and 
human cells (Longley et al., 2003). The activated metabolites of 5-FU: 
FdUMP, FdUTP, and FUTP have several toxic effects on the nucleotide 
metabolism. 
Unactivated 5-FU is degraded and detoxified by dihydropyrimidine 
dehydrogenase (DPD) which degrades pyrimidines such as 5-FU and similar 
compounds in a wide range of organisms from certain yeasts to humans. 
However, this  pathway is absent in S. cerevisiae (Andersen et al., 2006). 
 
Figure 7. Metabolic activation of 5-FU and uracil, with focus on enzymes which differ between S. 
cerevisiae and man. S. cerevisiae lacks DPD, UP, TP and TK. 
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5.6.2 Effects of 5-FU on DNA metabolism 
The 5-FU metabolite FdUMP forms a stable ternary complex with thymidylate 
synthase (TS or Cdc21p in S. cerevisiae) and the cofactor 5,10-
methylenetetrahydrofolate (MTHF) resulting in the inhibition of the synthesis 
of dTMP from dUMP and MTHF, see Figure 7. This inhibition results in an 
accumulation of dUMP and subsequently also dUTP. Under these conditions, 
dUTP and FdUTP both become used as substrates in DNA replication, see 
Figure 7. Uracil DNA glycosylase removes the uracil and 5-FU nucleobases 
that are misincorporated into DNA, but the lack of dTTP due to inhibition of 
TS sends the repair machinery into a futile cycle of mal-repairing the lesion 
with uracil and then removing the uracil again (Ladner, 2001). This eventually 
leads to loss of genome integrity, through the formation of double-strand DNA 
breaks, and cell death (Yoshioka et al., 1987). 
S. cerevisiae ung1 strains lacking uracil DNA glycosylase are therefore 
significantly protected from the toxic effects of 5-FU. The deletion of UNG1 
prevents the generation of abasic sites and causes the strain to accumulate 
massive amounts of T to U substitutions in its DNA. These substitutions are 
not detrimental in the short term. The next enzyme after Ung1p in the base 
excision repair process, Apn1p, nicks the DNA at the abasic position. The 
deletion of APN1 in combination with 5-FU is highly toxic, but its deletion 
does not cause an accumulation of abasic unrepaired sites, which implies that 
another repair process takes over and causes loss of viability (Seiple et al., 
2006). See chapter 3.2.1 about BER in this thesis. 
It should further be noted that 5-FU induced cell death in some human cell 
lines is dependent on p53 mediated apoptosis, which can be prevented by 
externally added uridine but not by externally added thymidine. This in turn 
implies that RNA mediated effects may be the primary cause of 5-FU toxicity, 
at least in some cells (Bunz et al., 1999). 
5.6.3 Effects of 5-FU on RNA metabolism 
5-FU has detrimental effects on most if not all parts of the RNA metabolism, 
from ribosome biogenesis to mRNA biosynthesis and processing. The reduced 
growth rate of 5-FU treated S. cerevisiae is in general more easily suppressed 
by the addition of UMP than of dTMP to the growth medium. This implies that 
RNA damage mediates most of the toxicity of 5-FU in S. cerevisiae (Hoskins 
and Butler, 2007). 
S. cerevisiae cells treated with 5-FU accumulate polyadenylated 27s 
rRNAs, and this is even more pronounced in the exosome exonuclease mutant 
rrp6, implying that 5-FU interferes with RNA processing in the exosome, of 
which Rrp6p is a component (Fang et al., 2004). 
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Interestingly, the 5-FU hypersensitivity of the rrp6 mutant can be 
suppressed by knocking out the pseudouridine synthase gene CBF5. Cbf5p and 
other pseudouridine synthases, which convert uridine to pseudouridine in small 
RNAs, can become covalently attached to 5-FU moieties that are present in 
RNA. It is likely that RNA molecules containing these probably toxic adducts 
are recognized as malformed and targeted for degradation by polyadenylation, 
but hyperaccumulate in the absence of Rrp6p (Hoskins and Butler, 2008; 
Spedaliere and Mueller, 2004) 
5-FU also becomes incorporated into U2-snRNA, where it blocks U2-
snRNA pseudouridylation. The hypopseudouridylated U2-snRNA makes the 
spliceosome defective in pre-mRNA splicing, which disturbs regulation of 
protein expression at the mRNA level (Zhao and Yu, 2007).  
Furthermore, 5-FU inhibits tRNA uridine methyltransferases and tRNA 
pseudouridine synthases, and thereby interfere with tRNA maturation 
(Frendewey et al., 1982; Gu et al., 1999; Santi and Hardy, 1987). 5-FU also 
acts synergistically to worsen the effects of tRNA modifying enzyme 
knockouts and elevated temperatures, both of which are known to destabilize 
tRNA (Alexandrov et al., 2006). This in turn implies that one toxic effect of 5-
FU treatment may be destabilization of tRNA (Gustavsson and Ronne, 2008). 
5.6.4 5-FU tolerance and sensitivity 
Human cancer cells and S. cerevisiae cells both have the ability to acquire 
resistance to 5-FU. Loss of function mutations in either of the uracil salvation 
proteins, the uracil permease Fur4p or the uracil phosphoribosyltransferase 
Fur1p thus renders yeast cells highly resistant to 5-FU, but at the same time 
makes them dependent on alternative pathways such as a functional de novo 
synthesis of UMP, or cytosine-to-UMP scavenging. Other known resistant 
genotypes in yeast are mutations that cause a loss of feedback inhibition of the 
carbamoyl phosphate synthetase protein Ura2p, overexpression of the 
uncharacterised gene YJL055w, and overexpression of the nucleotidase SDT1 
(Jund and Lacroute, 1970; Ko et al., 2008; Nakanishi and Sekimizu, 2002). 
Work in Aspergillus nidulans further suggested that loss of feedback 
inhibition of the arginine specific carbamoyl phosphate synthetase, and loss of 
function of the ornithine carbamoyl transferase, both can cause resistance to 5-
FU by increasing the do novo synthesis of UMP, through redirecting 
carbamoyl phosphate away from arginine synthesis toward UMP synthesis 
(Palmer et al., 1975). 
A gene expression analysis on colon cancer cell lines which were in the 
process of developing a 5-FU resistant phenotype, revealed a quite complex 
pattern of change in gene expression during the acquisition of an early weakly 
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resistant phenotype. After the transition to a strongly resistant phenotype, 
changes in the regulation of genes involved in pyrimidine metabolism could be 
observed, such as over-expression of the CAD and thymidylate synthase genes 
(Schmidt et al., 2004). However, it should be noted that changes in the 
pyrimidine metabolism, i.e. down regulation of pyrimidine catabolism and up 
regulation of de novo synthesis and scavenging, are generally present in 
cancers even in the absence of 5-FU selection, and probably reflect the faster 
proliferation rate of cancers cells (Weber, 2001). 
High expression of either thymidylate synthase, dihydropyrimidine 
dehydrogenase or thymidine phosphorylase has also been associated with 
resistance to 5-FU in tumours (Salonga et al., 2000). In contrast, a higher 
expression of orotate phosphoribosyltransferase has been associated with 
increased sensitivity to 5-FU in cancer cell lines (Taomoto et al., 2006). 
However, overexpression of  thymidine phosphorylase can also make some cell 
lines more sensitive to 5-FU (Schwartz et al., 1995). This apparent 
contradiction can possibly be explained by the fact that thymidine 
phosphorylase catalyses the first step of activation of 5-FU to 5-FdUMP, i.e. 
the conversion of 5-FU to 5-FdUrd. The latter is the growth inhibiting 
metabolite of 5-FU in some but not all cells (Codacci-Pisanelli et al., 2008). In 
other cells, where RNA toxicity mediated by 5-FUMP is more important, a 
redirection of 5-FU into 5-FdUrd might instead release the growth inhibition. 
5.7 Purine salvage and turnover 
S. cerevisiae appears to lack capacity to salvage extracellular purine 
nucleosides (Vickers et al., 2000). However, the purine nucleobases, adenine, 
guanine, and hypoxanthine are scavenged from the extracellular environment 
via the Fcy2p transporter (Ferreira et al., 1997). The nucleobases are then 
converted to nucleotides in a reaction with PRPP which is catalyzed by the 
phosphoribosyltransferases: Hpt1p for hypoxanthine and guanine, Apt1p for 
adenine, and Xpt1p for guanine and xanthine (Alfonzo et al., 1999; Ali and 
Sloan, 1982; Guetsova et al., 1999). 
The interconversion between the purine salvage pathways is asymmetric. 
Adenine can be used as a source for guanylates either via deamination of AMP 
by Amd1p, or direct deamination and phosphoribosylation by Aah1p and 
Hpt1p respectively, into the purine biosynthesis branch point intermediate 
IMP. However, guanine cannot be used as a source for adenylates. 
Hypoxanthine is salvaged directly to the branch point intermediate IMP and is 
therefore a source for both adenylates and guanylates (Saint-Marc and 
Daignan-Fornier, 2004; Saint-Marc et al., 2009). 
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AMP is converted into ADP by Adk1p, which is the major ATP-dependent 
adenylate (AMP) kinase. However, Adk1p only has minor dAMP kinase 
activity (Gu et al., 2005; Su and Russell, 1967). GMP is converted into GDP 
by Guk1p, which is the ATP-dependent guanylate (GMP) kinase. Guk1p also 
has dGMP kinase activity to a lesser degree (Konrad, 1992). 
Deamination of purines happens spontaneously. This generates xanthosine 
triphosphate, (d)XTP from (d)GTP, and hypoxanthosine triphosphate (d)ITP 
from (d)ATP. (d)XTP and (d)ITP are degraded by the Ham1p 
pyrophosphatase, which prevents their incorporation into DNA and RNA 
(Davies et al., 2012). In publication I, we found that overexpression of Ham1p 
also confers resistance to 5-FU, which suggests that Ham1p may also prevent 
the incorporation of 5-FU into RNA and DNA. In this context it should be 
noted that the UTPase Dut1p, which degrades dUTP to dUMP, also has 
activity against dITP (Tchigvintsev et al., 2011). 
There are also several other enzymes involved in purine nucleoside 
turnover, which could be of importance for detoxification of purine analogues: 
the Isn1p IMP-nucleotidase, the Pnp1p guanine and inosine ribohydrolase, the 
Ado1p adenosine kinase, the Gud1p guanine deaminase, and the Aah1p 
adenine deaminase (Saint-Marc and Daignan-Fornier, 2004). See Figure 8 for a 
summary of purine salvage and turnover. 
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Figure 8. Purine metabolism in S. cerevisiae with a focus on salvage and turnover. Thinner 
arrows mean that the reactions are known or expected to be of relatively minor importance. Most 




6-N-Hydroxylaminopurine, HAP, is converted into HAPMP by the Apt1p 
adenine phosphoribosyl transferase, and is further phosphorylated to HAPDP. 
HAPDP is assumed to be transformed to dHAPTP, via RNR and Ynk1p. 
dHAPTP is capable of ambiguous base pairing, and causes mutations by 
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replacing both dGTP and dATP during DNA replication. The toxicity of HAP 
is considered to be due to its role as a mutagen. However, it is conceivable that 
HAP could also affect RNA metabolism (Abdul-Masih and Bessman, 1986). 
Even though HAP is a mutagen, it can be utilized as a source of exogenous 
purines, and support growth of S. cerevisiae. This is dependent on HAP being 
converted into the purine biosynthesis branch-point intermediate IMP. This 
reaction is assumed to be catalysed by either of the deaminases Amd1p or 
Aah1p, since adenine aminohydrolases are known to have broad specificity 
against 6-N substituted adenines. Aah1p might play the more important role 
since its deletion confers sensitivity against HAP. Two other genes, among 
several known to be of importance for HAP tolerance, is the HAM1 nucleotide 
pyrophosphatase and the YJL055w gene, whose function is unknown (Noskov 
et al., 1996; Stepchenkova et al., 2005). In publication I, we found that 
overexpression of both HAM1 and YLJ055w also reduce the incorporation of 5-
fluorauracil into RNA. 
HAP is not used as an anticancer drug although it has shown therapeutic 
activity against transplanted animal tumours. The reason for this is that HAP is 
haemolytic in humans at doses below those that might produce anticancer 
effects (Dollinger and Krakoff, 1975). However, other purine analogues are 
used as drugs e.g. 6-mercaptopurine (6-MP) which is used for treatment of 
leukaemia (Adam de Beaumais et al., 2011). The 6-MP metabolite 
methylthioinosine monophosphate (meTIMP) is a potent inhibitor of purine de 
novo synthesis, which may contribute to the cytotoxicity of 6-MP. However, a 
knock-down of the thiopurine methyltransferase gene, which catalyzes one step 
in the conversion of 6-MP to meTIMP, did not significantly affect the toxicity 
of 6-MP in a human cell line (Karim et al., 2013). 
It is conceivable that 6-MP could also contribute to cytotoxicity by being 
incorporated into DNA or RNA. This is implied from the fact that reduced 
activity of inosine triphosphate pyrophosphatase (ITPA) correlates with more 
frequent hepatotoxicity during 6-MP treatment; ITPA degrades non-canonical 
nucleotide triphosphates, e.g. (d)ITP and (d)XTP and thereby prevents their 
incorporation into RNA and DNA (Davies et al., 2012; Tanaka et al., 2012). In 
manuscript III we found that a polymorphism of the ITPA gene, which reduces 
the enzymatic activity with 78% in heterozygous carries (Simone et al., 2013), 





6 Genetic association studies 
The correlation, and sometimes also the causation between phenotypes and the 
underlying genotypes can be studied in different ways. In a forward genetic 
genome-wide association study, many genetic polymorphisms in each genome 
are simultaneously analysed in an attempt to find which of them associate with, 
i.e. correlate with, a given phenotype. However, genetic association studies do 
not necessarily have to be genome-wide. In manuscript III we used genetic 
information about polymorphisms at five specific loci to build a model for 
correlation with 5-FU toxicity in cancer patients. 
In contrast, a reverse genetics microarray study can determine which 
phenotypes, i.e. changes in mRNA expressions levels, are caused by a given 
genetic modification. In publication II we investigated the effect of a mutation 
in the Rph1p transcription factor that abolishes its histone demethylase activity 
on genome-wide gene regulation. 
6.1 Microarray analysis and gene expression 
A commonly used method to measure gene expression is the Affymetrix 
Genechip microarray platform, which was used in publication II. To measure 
the abundance of an mRNA transcript, a Genechip array has a set of probes 
that hybridize to different parts of each mRNA transcript. It has furthermore 
both perfect match and mismatch probes, which facilitates the transformation 
of microarray signal values to mRNA transcript levels. 
In order to estimate the expression level of each RNA transcript, different 
normalization methods can be used. In publication II we used the GC-RMA 
normalization method (Wu and Irizarry, 2004). The normalization of 
microarrays is an area of development, and an alternative normalization 
method is the IRON algorithm (Welsh et al., 2013). 
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6.1.1 Limma 
Microarray mRNA expression can be analysed using the package Linear 
Models for Microarray Data, limma, which is available in R, a programming 
environment for statistical analysis. Limma accepts log2 transformed 
expression data, which is the type of output data generated by the GC-RMA 
normalization. Limma can be used to fit a generalized linear model between 
the mRNA expression data for each gene, and the explanatory variables e.g. 
experimental conditions such as the genetic modifications studied in 
publication II. However, if limma is used with the default settings, it will 
simply model an ordinary linear regression between the mRNA expression 
levels and the explanatory variables using the least squares method. 
Limma facilitates the finding of sets of significantly differently expressed 
genes in comparisons between different experimental conditions by using 
false-detection-rate correction of P-values, smoothening of sample variance 
and moderation of the t-test for differential expression (Smyth, 2004). 
An interaction formula in the Wilkinson-Rogers notation is frequently used 
to describe a model between a dependent variable and explanatory variables 
(Wilkinson and Rogers, 1973). An interaction formula of this kind can be 
supplied to both the limma package used in publication II, and to the glm 
function used for logistic regression in manuscript III. The interaction formula 
provides the modelling program, e.g. limma or glm, with information on 
whether to include interactions between explanatory variables, and whether or 
not the fitted model should pass through origo, i.e. the dependent variable 
should be zero if all explanatory variables are zero (Wilkinson and Rogers, 
1973). 
6.2 Generalized linear models 
Depending on the nature of the explanatory and dependent variables, different 
regression methods can be used to construct a model, and test the significance 
of the contribution from each explanatory variable. A common regression 
method is linear regression, which tests the dependence of a continuous 
variable on one or more variables. To build models with a dependent variable 
that is not continuous, the regression method can be generalized by a 
transformation of the dependent variable. In contrast to a continuous variable, 
the dependent variable in manuscript III is a dichotomous variable with toxicity 
or no toxicity as possible outcomes. The regression used to build a model with 
a dependent dichotomous variable is called logistic regression. Logistic 
regression builds a model between the explanatory variables, the regression 
coefficients of which become determined, and the transformed dependent 
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variable, called the logit. The logit is the logarithm of the odds that correspond 
to the probability of the outcome (Petrie and Sabin, 2005). 
An iterative algorithm performs a maximum likelihood estimation in 
logistic regression and other types of generalized linear modelling. This 
procedure estimates the regression coefficients for each explanatory variable of 
the model in such a way that the data of the explanatory variables has the 
highest possible probability of generating the data of the dependent variable. In 
logistic regression, the regression coefficients correspond to the natural 
logarithm of the odds ratio for an increase in the corresponding explanatory 
variable. To assess the significance of explanatory variables in the model, or to 
assess the adequacy of fit between the model and the data, the likelihood ratio 
statistic is used. This statistic is often referred to as deviance (Petrie and Sabin, 
2005). 
In manuscript III we used the c-statistic for evaluating the performance of 
the model in correctly classifying patients into either the 5-FU sensitive, or 5-
FU insensitive group. The c-statistic has a possible range between 0.5 and 1. A 
value of 0.5 indicates that the model lacks classification performance, and a 
model with value 1 means that it classifies perfectly (Petrie and Sabin, 2005). 
A hypothetic model with a c-statistic of 1 could thus be considered to explain 
all variation in the dependent variable, and could consequently be considered 





The general aim of this thesis has been to use the budding yeast S. cerevisiae as 
a model organism to study mechanisms involved in cancer, with the aim of 
using the knowledge gained in yeast to improve anticancer therapies. 
Specifically, I have investigated the mechanisms of resistance to the 
nucleobase analogues 5-fluorouracil (5-FU; publication I) and 6-N-
hydroxylaminopurine (HAP; manuscript IV).  5-FU is a cytotoxic drug used in 
the treatment of cancer, whereas 6-N-hydroxylaminopurine is a purine 
analogue used primarily to study the metabolism of purine analogues. The 
details of the metabolism of purine analogues are important for the 
understanding of the fate of other purine analogues such as 6-mercaptopurine, 
which are used for the treatment of leukaemia. In manuscript III, the effect on 
5-FU sensitivity of a mutation in the human orthologue of one of the genes 
identified in publication I was investigated.  
I have also participated investigating the mechanism(s) of transcriptional 
regulation of the yeast Rph1p transcription factor, which functions downstream 
of several nutrient sensing pathways (publication II). These nutrient signalling 
pathways are conserved in eukaryotic evolution, and are a part of the stimulus 
a cell needs for the decision whether to proliferate or to arrest. Much research 
has been devoted to gaining a better understanding of the mechanisms behind 
the sustained proliferative signalling in cancer. A better understanding of the 
downstream molecular consequences of nutrient signalling could therefore also 
help to elucidate the mechanisms behind cancer.  
7.1 Publication I 
Through mutations in single tumour cells and subsequent clonal expansion, 
tumours often develop resistance to anticancer drugs. Possible resistance 
mechanisms include mutations in the molecular target(s) of the drug that make 
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these targets less sensitive, as well as improved degradation and exclusion of 
the drug. Furthermore, some drugs need to be converted from a pro-drug to an 
active drug, a step that can also be affected by mutations. In publication I, we 
used a gene overexpression screen in S. cerevisiae to find proteins that may be 
involved in resistance to the cytotoxic anticancer drug 5-FU. We also 
characterized the mechanisms of the resistance conferred by overexpression of 
some of the genes identified in our screen. 
7.2 Publication II 
Transcription factors lie at the end of many signal transduction pathways, and 
their activation changes the proteome to adapt the cell to the cause of the 
signal. Stimuli which induce signal transduction can for example be nutrients, 
stressors or cell to cell signalling. 
The Rph1p transcription factor lies downstream of the nutrient sensing 
pathways of TORC1 and PKA. In the exponential growth phase, Rph1p 
together with the closely related protein Gis1p repress many genes 
redundantly, whereas other genes instead are activated independently by 
Rph1p and Gis1p in the post diauxic shift growth phase. Genes that are 
regulated by Rph1p and/or Gis1p have STRE and PDS elements in their 
promoters, to which the two proteins bind. Rph1p, unlike Gis1p, has two 
known roles; it is a transcription factor, but it also has histone demethylase 
activity. Modification of histone acetylation is one of the major mechanism by 
which transcription factors influence gene expression, which suggested that the 
histone demethylase activity of Rph1p might be important for its role as a 
transcription factor. We carried out transcriptome profiling of both an rph1 
deletion mutant and an rph1 demethylase-deficient point mutant using 
microarray technology in order to elucidate the connection between the histone 
demethylase activity of Rph1p and its transcription factor activity. 
7.3 Manuscript III 
Genetic variation can render humans hypersensitive to drugs. For example, 
polymorphisms causing reduced activity of the 5-FU degrading enzyme 
dihydropyrimidine dehydrogenase are associated with severe toxicity in 
patients receiving 5-FU treatment. Similarly, a polymorphism in the inosine 
triphosphate pyrophosphatase gene ITPA, which causes reduced enzyme 
activity, has been shown to influence toxicity from 6-mercaptopurine. 
The human ITPA gene is the orthologue of the S. cerevisiae gene HAM1, 
which we found in publication I to confer resistance to 5-FU when 
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overexpressed. By reanalysing toxicity data from a clinical trial on patients 
treated with a 5-FU based regimen and genotyping tissue samples from the 
same patients for the ITPA polymorphism, we aimed to elucidate if the ITPA 
polymorphism correlates with 5-FU toxicity. 
7.4 Manuscript IV 
To gain more knowledge concerning tolerance against nucleobase analogues, 
we did another gene overexpression screen in S. cerevisiae for resistance to the 
mutagenic purine analogue 6-N-hydroxylaminopurine (HAP). A gene involved 
in resistance to nucleobase analogues can be more or less specific. By finding 
genes involved in resistance to the purine analogue HAP, and test the effect of 
those genes on resistance to 5-FU resistance, we aimed to find more genes 
which could influence 5-FU resistance. We also aimed to get a deeper 
understanding of genes known to confer 5-FU resistance by testing the effect 
of those genes regarding HAP resistance. Furthermore, we investigated if 
genetic interactions between 5-FU and HAP resistance genes could reveal 




8 Results and discussion 
8.1 Publication I 
In publication I, we sought to find genes which confer 5-FU resistance when 
overexpressed in S. cerevisiae. We found six genes: 
 The subunits of the CPSase, CPA1 and CPA2, which catalyze the first step 
in the de novo synthesis of arginine. 
 The CPSase, URA2, which catalyze the first step in the de novo synthesis of 
UMP. 
 The HMS1 basic helix-loop-helix transcription factor which is known to 
positively regulate pseudohyphal growth. 
 The YJL55w gene encoding a protein of unknown function, but of which 
overexpression is known to confer resistance to 5-FU, and deletion is 
known to confer sensitivity to purine analogues, e.g. HAP. 
 The HAM1 gene, which encodes a (d)ITP and (d)XTP pyrophosphatase. 
The overexpression of HAM1 is known to confer resistance to 5-
bromodeoxyuridine, and the deletion of HAM1 is known to confer 
sensitivity to purine analogues, e.g. HAP. 
8.1.1 Pyrimidine de novo synthesis 
The Ura2p enzyme and the Cpa1p/Cpa2p enzymatic complex catalyse the 
synthesis of the same compound, carbamoyl phosphate, which is a precursor in 
both UMP and arginine biosynthesis. This suggests that the Cpa1p/Cpa2p 
enzymatic complex could confer 5-FU resistance by increasing the synthesis of 
UMP, which would dilute the toxic 5-FU metabolite 5-FUMP. To this end we 
investigated if a functional UMP synthesis pathway is required to confer the 5-
FU resistance. We found that a functional UMP synthesis pathway is required 
for 5-FU resistance mediated by these genes. We further investigated if 
alterations of the arginine biosynthesis pathway could influence 5-FU 
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resistance. Based on a model where available carbamoyl phosphate can be 
channelled into either arginine or UMP synthesis, we argued that blocks in 
arginine synthesis could divert more carbamoyl phosphate into the synthesis of 
UMP, and thereby contribute to 5-FU resistance. In accordance, we found that 
blocks in arginine biosynthesis conferred a moderately increased 5-FU 
resistance. We also investigated if arginine could block the resistance conferred 
by Cpa2p overexpression. The logic behind this was that the enzymatic activity 
of Cpa2p is largely dependent on Cpa1p, and CPA1 is downregulated by 
arginine. We found that arginine could indeed block 5-FU resistance conferred 
by CPA2 overexpression. However, this required a high arginine concentration 
and growth on ammonium-less media. 
8.1.2 Mechanisms of resistance 
To broadly characterize the mechanisms of resistance by each gene, we tested 
if the overexpression of each gene affected either uracil or 5-FU on the level of 
cellular uptake or expulsion, and incorporation into RNA. We assayed this by 
using 14C radiolabeled nucleobases i.e. uracil and 5-FU. 
The overexpression of the transcription factor HMS1 displayed the same 
pattern as overexpression of the CPA1 and CPA2 genes in that it blocked both 
uptake and RNA incorporation of both 5-FU and uracil. Since we also found 
that 5-FU resistance resulting from HMS1 overexpression was dependent on a 
functional pyrimidine de novo synthesis, this suggested that HMS1 acts by 
upregulating the pyrimidine de novo synthesis. In addition to the diluting effect 
of de novo synthesized UMP on the incorporation of externally supplied 5-FU 
or uracil into RNA, the upregulated de novo synthesis resulting from either 
HMS1, CPA1 or CPA2 overexpression could also feedback inhibit the uptake 
of both uracil and 5-FU through the Fur4p uracil permease; de novo 
synthesized UMP has been shown to be degraded to uracil, and uracil has been 
shown to downregulate FUR4 (Grenson, 1969; Seron et al., 1999). 
In contrast, the overexpression of YJL055w and HAM1 did not reduce the 
uptake of either uracil or 5-FU, but instead specifically reduced the 
incorporation of 5-FU into RNA while having no effect on incorporation of 
uracil. This suggested that HAM1 and YLJ055w act by detoxifying 5-FU or a 5-
FU metabolite e.g. 5-FUTP. In accordance with this, Ham1p pyrophosphatase 
has been found to dephosphorylate the purine nucleotides (d)XTP and (d)ITP 
to (d)XMP and (d)IMP, thereby preventing the incorporation of these non-
canonical nucleotides into RNA and DNA. Overexpression of HAM1 has 
moreover been shown to confer resistance to 5-bromodeoxyuridine, which 
suggests that Ham1p also might detoxify non-canonical pyrimidine analogues 
62 
(Davies et al., 2012; Takayama et al., 2007). We conclude that this is a likely 
mechanism for the effect of HAM1 overexpression on 5-FU resistance. 
8.1.3 Resistance to 5-FU-related compounds 
We furthermore tested if overexpression of the resistance genes also confer 
resistance to related compounds. We found that the resistance genes also 
confer resistance to 5-fluorocytosine and 6-azauracil, but differed in their 
ability to confer resistance to methotrexate and 5-fluoroorotic acid (5-FOA). 
The peculiarity of lack of resistance to the 5-FU precursor 5-FOA by 
overexpression of any of the CPSases, is presumably because CPSase 
overexpression, and coupled overexpression of the plasmid marker URA3 
would also contribute to the activation of 5-FOA into 5-FU; pyrimidine de 
novo synthesis has a feed-forward mechanism. Overexpression of Cpa1p and 
Cpa2p conferred resistance to the antifolate methotrexate. In contrast Ura2p 
did not confer resistance. However, the lack of resistance from overexpression 
of Ura2p could hypothetically be due to a more increased arginine synthesis in 
the Cpa1/Cpa2p overexpressors compared to the Ura2p overexpressor. 
Arginine could then influence the resistance to methotrexate through some 
unknown mechanism e.g. increased synthesis of nitrogen oxide. 
8.2 Publication II 
In the log phase Gis1p and Rph1p mainly act as redundant repressors of gene 
expression. This is inferred from the fact that genes are mainly upregulated i.e. 
derepressed in the double knockout gis1 rph1 strain in the log phase. In 
contrast to the log phase, Rph1p and Gis1p act as both activators and 
repressors, and target different sets of genes in the PDS phase (Orzechowski 
Westholm et al., 2012). 
A H235A mutation in Rph1p removes its histone demethylase activity. By 
comparing mRNA expression patterns in different mutants, we sought to 
identify the contribution of the Rph1p enzymatic activity to regulation of gene 
expression. We proceeded to compare gene expression in wild type and mutant 
yeast strains. The included mutants were: gis1Δ, rph1Δ, rph1-H235A, gis1Δ 
rph1Δ, and gis1Δ rph1-H235A. Analyses of the transcriptomes were done in 
both the log and PDS growth phases. Surprisingly, we found that the changes 
in gene expression in the rph1-H235A mutants were relatively small; the 
transcriptome of the rph1-H235A mutant was thus much more similar to that of 
the wild type than to that of the rph1Δ strain, and the transcriptome of the gis1 
rph1-H235A double mutant was more similar to that of the gis1Δ mutant than 
to that of the gis1Δ rph1Δ double mutant. 
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8.2.1 The effect of the rph1-H235A mutation on gene expression 
The rph1-H235A demethylase mutation affected gene expression more in PDS 
phase, where 25 genes become upregulated due to the mutation, than in log 
phase. However, this is still a low number of genes compared to those affected 
in the rph1∆ strain. We further found that although relatively few genes were 
differently expressed above the 1.5-fold threshold that we used in the rph1-
H235A mutant, genes that were up or downregulated in the rph1∆ mutant were 
also generally affected in the same direction in the rph1-H235A mutant, but to 
a smaller degree. This suggests that the transcriptional activity of Rph1 is 
generally impaired in the rph1-H235A mutant, but the effect is big enough to 
be significant only for a small number of genes. The result of this comparison 
between sets of genes was also significant when the small number of genes that 
were significantly regulated at least 1.5-fold by the rph1-H235A mutant were 
excluded. We concluded that while most of the transcriptional regulation 
mediated by Rph1p seems to be largely independent of its demethylase 
activity, this regulation is to some extent enhanced by the same demethylase 
activity. 
A total of 45 genes were significantly affected in one of the two growth 
phases (log or PDS) by the rph1-H235A mutation in either of the wild type or 
gis1 backgrounds. Several of these genes are involved in sporulation, and 
several are also located close to (less than 30 kb) telomeres. Interestingly, two 
genes, SNZ1 and SNO1, which are downregulated in both the rph1∆ and rph1-
H235A strains, have been found to be derepressed in set2 and rpd3 mutants. 
This result indicates that at least these two genes, but most probably more of 
the 45 genes, are regulated by Rph1p-dependent demethylation of H3K36. 
There are other groups of genes whose expression seems to be affected by 
the rph1-H235A mutation, but the effect of the mutation on the expression of 
each individual gene was too small to be significant. However, as noted above, 
when these genes are analysed as a group, the effect of the rph1-H235A 
mutation becomes significant. One example is the 290 genes that have been 
found to be affected by a set2 deletion. In accordance with the opposing effect 
of Set2p and Rph1p on H3K36 methylation, the rph1-H235A mutation affects 
the transcription of these genes, as a group, in the opposite direction of set2. In 
the PDS phase, the rph1-H235A mutation furthermore increased the expression 
of genes within 20 kb of the telomeres, when considered as a group. Moreover, 
the demethylase activity of Rph1p seems to be important for the repression of 
genes involved in meiosis and sporulation. This is inferred from the fact that 
genes whose expression is increased or decreased more than 5-fold during 
sporulation are affected by the rph1-H235A mutation, when considered as a 
group. The effect is particularly pronounced for genes that are repressed in the 
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log phase, and the effect of the rph1-H235A mutation is, surprisingly, more 
pronounced in this case than the effect of either the gis1 or rph1 deletions. 
8.3 Manuscript III 
The human orthologue of the S. cerevisiae gene HAM1, the overexpression of 
which we found to confer resistance to 5-FU in publication I, is ITPA. Reduced 
activity of ITPA due to the 94 C>A ITPA polymorphism, correlates with more 
frequent toxicity during treatment with the purine analogue 6-MP (Tanaka et 
al., 2012). We genotyped blood and tissue samples previously obtained from 
colorectal adenocarcinoma patients for the ITPA 94 C>A polymorphism. The 
patients were genotyped for the UGT1A1 *28, MTHFR 677 C>T, ABCB1 3435 
C>T, and TYMS *2 or *3 polymorphisms in a previous study (Glimelius et al., 
2011) and were also examined for clinically relevant early toxicity resulting 
from the treatment by a combinatorial regimen with irinotecan and 5-FU. It 
was possible to genotype the ITPA 94C>A polymorphism for 126 out of 140 
saved blood or tissue samples from these patients. 14 of the patients were 
heterozygous for the ITPA polymorphism, and none were A/A homozygous, 
which does not deviate significantly from a Hardy-Weinberg equilibrium. 
To determine the contribution from the ITPA polymorphism to clinically 
relevant early toxicity a multivariate logistic regression model was built. To 
build this model the above mentioned polymorphisms were included since they 
had previously been found to correlate with clinically relevant early toxicity. 
First, a univariate analysis was done for each polymorphism to determine if the 
effect of the polymorphic alleles on toxicity were better explained by an 
additive or dominant allelic model. Two alleles were found to significantly 
(P<0.05) influence toxicity when considered in isolation; the MTHFR 677 T 
allele correlated with a decreased toxicity, and the ABCB1 3435 T allele 
correlated with a significantly increased toxicity. Subsequently, when the 
multivariate logistic regression was done, the UGT1A1 locus, but neither the 
ITPA nor the TYMS locus, could be directly fitted into the model. To fit a 
polymorphism into the model all regression coefficients had to be significant at 
P<0.05, and the improvement of the goodness-of-fit of the model had to be 
significant P<0.05 in a likelihood ratio test. 
The model was then extended to test for contributions from genetic 
interactions. For example, one could reason that TYMS, thymidylate synthetase 
and MTHFR, methylenetetrahydrofolate reductase, should show some genetic 
interaction since they both presumably influence the same 5-FU related DNA 
toxicity. However, TYMS could not be fitted into the model by any genetic 
interaction. ITPA, on the other hand, could be fitted into the model when a 
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genetic interaction between the ITPA and ABCB1 loci was included into the 
model. The regression coefficient of this interaction was negative, which 
means that the simultaneous presence of the ITPA 94 A, and the ABCB1 3435 
T alleles has a less than additive effect on clinically relevant early toxicity. A 
possible molecular explanation for this interaction could be that ITPA 
dephosphorylates a 5-FU metabolite into a fluorinated nucleotide 
monophosphate which is then pumped out from the cell by the ABCB1 efflux 
pump. If the ABCB1 substrate concentration is substantially reduced by the 
ITPA defect, then the presence or absence of ABCB1 might be of less 
importance for toxicity. 
To get a measure of the goodness-of-fit of the model the c-statistic was 
calculated. A c-statistic of 0.5 would have indicated that the model had no 
discriminatory power, and a c-statistic of 1.0 would have indicated that the 
model would have been perfectly discriminatory between toxicity and no 
toxicity. The c-statistic of the full model including ITPA was calculated to 
0.73, which indicates that the model is reasonable good, but does not explain 
all variation in toxicity between patients. Other yet to be identified 
polymorphisms could presumably be included to strengthen the discriminatory 
power of the model. 
8.4 Manuscript IV 
To get a better understanding of detoxification and resistance to toxic 
nucleobase analogues, we screened a shuttle vector based genomic library for 
genes which confer resistance to the mutagenic purine analogue HAP, when 
overexpressed in S. cerevisiae. The genes which were found to confer HAP 
resistance, and the genes which conferred resistance to 5-FU in publication I 
were all tested for genetic interactions affecting both 5-FU and HAP resistance. 
The new genes we found to confer resistance to HAP were: 
  The DUT1 gene encoding deoxyuridine triphosphate pyrophosphatase 
(dUTPase), an enzyme required for synthesis of thymidylate and DNA. 
dUTPase has also been found to be essential for genomic stability. Dut1p, 
which primarily dephosphorylates the pyrimidine dUTP, has furthermore 
been shown to dephosphorylate the purine deoxyribonucleotide dITP. 
However, DUT1 overexpression, surprisingly, only conferred resistance to 
HAP, but not 5-FU; while the DUT1/dut1 heterozygous strain was only 
sensitive to 5-FU, but not HAP. 
 The APT2 gene, a paralogue of the APT1 gene, which encodes adenine 
phosphoribosyltransferase. However, the APT2 encoded protein has not 
been shown to possess adenine phosphoribosyltransferase activity. We 
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found that while APT2 overexpression conferred weak resistance to HAP, 
the apt2 deletion strain was not HAP sensitive. 
 The ATR1 gene encoding a membrane bound efflux pump belonging to the 
major facilitator superfamily, which has been shown to confer resistance to 
the nitrogen-containing heterocyclic compound aminotriazole, and also 
borate. ATR1 overexpression conferred strong resistance to both 5-FU and 
HAP, but the atr1 deletion strain was only sensitive to 5-FU, and not to 
HAP. 
 The ADE4 gene which encodes the enzyme 5-phosphoribosyl-1-
pyrophosphate amidotransferase, Ade4p. Ade4p catalyses the first step in 
the de novo synthesis of purine nucleotides. ADE4 overexpression 
conferred resistance to HAP, and also weak resistance to 5-FU.  
Two genes, YJL055w and HMS1, which conferred resistance to 5-FU in 
publication I, also conferred resistance to HAP in the genetic interaction assay. 
However, these two genes were not recovered in the genomic library screen for 
HAP resistance. The gene that was used as a positive control for HAP 
resistance, HAM1, was however recovered five times in the screen. This 
suggests that the screen was quite exhaustive, but still not complete. 
8.4.1 Genetic interactions and models for HAP and 5-FU resistance 
We included the deletion strains amd1, aah1, and ade1 in our studies of genetic 
interactions in order to further elucidate the possible molecular functions of the 
cloned resistance genes. From the genetic interactions found, possible 
molecular mechanisms of resistance to HAP or 5-FU were proposed. 
The strong genetic interaction between the HAM1 overexpression, and the 
amd1 deletion regarding 5-FU resistance could be due to an effect of the purine 
nucleotide balance on 5-FU metabolism. However, a more likely possible 
explanation of this effect is that Amd1p, which is known to deaminate AMP, 
also deaminates the 5-FU metabolite 5-FCMP. 
Interestingly, although they are not members of the same gene family as 
ATR1, some of the genes in the ATP-binding cassette (ABC) family of drug 
efflux transporters have been found to confer resistance to 5-FU, 6-thioguanine 
and 6-mercaptopurine in human cell lines. Thus, 5-FU resistance was shown to 
be conferred by the ABC efflux pump MRP5 through ATP-dependent transport 
of the monophosphorylated nucleotides 5-FUMP and 5-FdUMP (Chen et al., 
2001; Pratt et al., 2005). This is analogous to the suggested role of Atr1p in our 
models for HAP and 5-FU resistance, where Atr1p is proposed to pump out the 
monophosphorylated nucleotides dHAPMP and 5-FCMP. 
DNA toxicity due to increased mutagenesis is the primary mode of action of 
HAP that has been proposed by others (Abdul-Masih and Bessman, 1986). Our 
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results are consistent with this hypothesis. In contrast, 5-FU is also toxic to 
RNA metabolism. In addition to its known inhibition of tRNA pseudouridine 
synthases e.g. Pus1p and tRNA uridine methylases, 5-FU may also affect RNA 
metabolism by being converted into 5-FCTP and incorporated into RNA. 
Analogously to the inhibition of tRNA uridine methylases, 5-FCTP 
incorporation into tRNA could inhibit the tRNA methylases such as Trm4p. 
The inhibition of multiple tRNA modifying enzymes e.g. Pus1p and Trm4p 
could in turn cause tRNA instability (Gustavsson and Ronne, 2008) and 
possibly also erroneous tRNA mediated gene regulation. 
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9 Conclusions and future perspectives 
9.1 Pharmacogenomics of 5-fluorouracil 
The (d)ITP pyrophosphatase gene HAM1 in S. cerevisiae, the overexpression 
of which we found to confer 5-FU resistance in publication I, and HAP 
resistance in manuscript IV, is the orthologue of the human gene ITPA. In 
manuscript III we found that the 94C>A polymorphism in the ITPA gene 
correlated with an increased incidence of toxicity from combined 5-FU and 
irinotecan treatment in cancer patients. However, this result, which was based 
on logistic regression modelling, was only significant when we included a 
genetic interaction between the ITPA 94C>A polymorphism, and the 3435C>T 
polymorphism in the ABCB1 ATP-binding cassette gene. This genetic 
interaction was negative, which means that the co-occurrence of both 
polymorphisms has a less than additive effect on the incidence of toxicity. 
With data from more 5-FU treated patients it could be possible to more 
stringently determine the correlation between 5-FU sensitivity and the ITPA 
polymorphism, i.e. score the correlation without taking genetic interactions 
into account. The correlation could presumably be established by a regular 
Fisher’s exact test from a larger patient group. Moreover, by studying the 
effects of the ITPA polymorphism on other combination treatments or on 
treatment with 5-FU alone, any conceivable effects of irinotecan could be ruled 
out.  
9.2 Resistance to nucleobase analogues in S. cerevisiae 
As discussed in manuscript IV, 5-FU seems to target mainly RNA metabolism 
in yeast, but also to a lesser extent DNA metabolism. It would benefit the 
elucidation of 5-FU metabolism if it was possible to specifically target either 
DNA or RNA metabolism with 5-FU. 
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Deoxyuridine is claimed to not be utilizable by S. cerevisiae (Kurtz et al., 
2002), see also chapter 5.4 this thesis. This suggests that it should not be 
possible to specifically target DNA metabolism with 5-fluorodeoxyuridine, 
which could otherwise have been converted to 5-FdUMP, which presumably 
would inhibit thymidylate synthetase, but not interfere with RNA metabolism.  
However, HAM1 overexpression has been shown to confer resistance to 5-
bromodeoxyuridine (Takayama et al., 2007). This suggests the possibility that 
DNA metabolism might still be specifically targeted by modified pyrimidine 
deoxyribosides such as 5-fluorodeoxyuridine, contrary to the earlier results. 5-
Fluorodeoxyuridine, if it could be used to specifically target the DNA 
metabolism, would according to our model in manuscript IV result in different 
resistance phenotypes due to overexpression than 5-FU. HAM1 overexpression 
would thus be expected to confer lower resistance, and DUT1 overexpression 
to confer relatively higher resistance to the drug. It would furthermore be 
possible to study drug interactions between the DNA toxic 5-
fluorodeoxyuridine, and other cell cycle inhibitors. 
A yeast immobilization technique makes it possible to study S. cerevisiae 
that are in cell cycle arrest, with downregulated CDC28 and CLN1, but still 
retaining a high fermentative capacity (Nagarajan et al., 2014). Since DNA 
synthesis is absent under these conditions, this technique could make it 
possible to more specifically study the RNA toxicity of both 5-FU, and HAP. 
HAP is considered to be mutagenic, and toxic for DNA metabolism, but could 
hypothetically also target RNA metabolism. 
9.2.1 5-FU and tRNA 
A model for 5-FU toxicity is proposed in manuscript IV. In this model 5-FU 
also targets Trm4p in addition to its known targets, see chapter 5.6.3 in this 
thesis. Trm4p methylates the 5’ position of cytidines in several tRNAs. This is 
of importance for gene regulation in response to oxidative stress (Chan et al., 
2012). The methylation status of cytidines in tRNA can be determined by 
bisulfite treatment of RNA, which transforms cytidine, but not 5’-
methylcytidine to uridine, followed by sequencing of cDNA generated from 
treated RNA (Schaefer et al., 2009). Consequently, it would be possible to 
assay the impact of 5-FU on Trm4p-mediated tRNA cytidine methylation with 
this method. 
Another tRNA methylase, Trm9p, methylates the 5’ position of uridines in 
some tRNAs, and is thereby involved in the translational regulation of DNA 
damage response (DDR) genes such as the ribonucleotide reductase subunit 
genes RNR1 and RNR3 (Begley et al., 2007). It would be interesting to 
investigate whether 5-FU mediated RNA toxicity causes a translational 
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downregulation of DDR genes such as RNR1 and RNR3, and thereby increases 
the DNA toxicity per se. However, since the dysregulation would happen at the 
translational level, RT-PCR or microarrays could not be used to assay this. 
Conceivably, one could instead use protein electrophoresis or possibly 
quantitative protein mass spectrometry. 
In addition to the lethal effects of 5-FU on RNA metabolism, 5-FU might 
cause an arrest in the G1 phase of the cell cycle, which could be mediated by 
tRNA destabilization (Gustavsson and Ronne, 2008). Initially, this could be 
investigated in S. cerevisiae treated with growth inhibiting, but not lethal, 
concentrations of 5-FU; a non-lethal concentration would presumably be 
required to investigate an ordered regulated response, such as cell cycle arrest.  
tRNA destabilization prevents tRNA maturation. GCN4 has moreover been 
shown to be upregulated by the presence of immature tRNA in the nucleus, and 
prevent the progression of the cell cycle from G1 to S by delaying the 
accumulation of late G1 cyclins, see chapters 3.3.1 and 5.6.3 in this thesis. 
Thus, 5-FU mediated tRNA toxicity could possibly affect the transcriptional 
status of GCN4 and the late G1 phase cyclins. 
9.2.2 5-FU and HAP metabolism and degradation 
Possible models for 5-FU and HAP metabolism and toxicity are discussed in 
manuscript IV, but several of the proposed molecular mechanisms remain to be 
biochemically validated. For example, it is important to determine if the 
adenine deaminase Amd1p can deaminate 5-FCMP, CMP or both; in particular 
the ability to deaminate 5-FCMP would be important for its role in 5-FU 
detoxification. The suggested 5-FCMP deaminase activity of Amd1p would 
have to be tested in vitro, but a possible CMP deaminase activity of Amd1p, 
which if found would imply 5-FCMP deaminase activity, could be tested by 
genetics.  Thus, a comparison of an urh1 cdd1 fcy1 ura3 strain to an urh1 ccd1 
fcy1 ura3 amd1 strain, for the ability to utilize externally provided cytidine as a 
source of pyrimidines, might reveal if Amd1p has CMP deaminase activity. If 
the former, but not the latter strain is able to grow in the presence of cytidine, it 
would strongly imply that Amd1p also has CMP deaminase activity in addition 
to its known AMP deaminase activity. Since Amd1p has been found to be 
allosterically regulated by ATP, this should be tested on both fermentable and 
non-fermentable carbon sources. 
In manuscript IV, we also discussed the possibility that Ham1p causes 5-FU 
resistance by being a pyrophosphatase acting on 5-FCTP. It is possible to assay 
this activity by combining the purified Ham1p enzyme and inorganic 
pyrophosphatase, and detecting the generation of phosphate after the addition 
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of 5-FCTP as a substrate. However, the proposed Ham1p substrate 5-FCTP 
would first have to be synthesized. 
9.3  Nutrient signalling and metabolic regulation 
In publication II we found that the histone lysine demethylase (H3K36) activity 
of Rph1p was largely dispensable for its role in transcriptional regulation. This 
raises the question what the primary role of the Rph1p-dependent histone 
demethylation is. One possible clue are results obtained in other organisms, see 
chapter 2.2.2 in this thesis, that have shown that H3K36 methylation 
preferentially enhances the non-homologous end joining (NHEJ) DNA repair 
pathway (Fnu et al., 2010); thus H3K36 methylation could be important for the 
choice between DNA repair pathways. This could be of importance for the 
generation of mutations, since NHEJ is error prone compared to the other 
major repair pathway homologous recombination repair (HRR). See chapter 
3.2.3 and 3.2.4 in this thesis. 
Transcribed DNA has been found to be more vulnerable to mutagenesis 
(Kim et al., 2007) and Rph1p positively regulates gene expression mainly in 
the PDS phase (Orzechowski Westholm et al., 2012) when mitochondria are 
active, and, consequently, the burden of DNA damaging reactive oxygen 
species (ROS) is comparably high. This implies that genes regulated by Rph1p, 
and also Gis1p, in the PDS phase could be more vulnerable to DNA damage 
due to ROS exposure. Hypothetically, the Rph1p histone demethylase activity, 
which counteracts H3K36 methylations by Set2p inside genes, could therefore 
be of importance for reducing the incidence of mutations resulting from NHEJ 
mediated DNA repair, see chapter 2.2.2 in this thesis. 
Hypothetically, the choice between NHEJ and HRR would mainly affect 
diploid cells in the G1 phase of the cell cycle since HRR is the preferred repair 
pathway in the S and G2 phases of the cell cycle, and only diploid cells have a 
homologous DNA template in the G1 phase (Kadyk and Hartwell, 1992; 
Mathiasen and Lisby, 2014; chapters 3.2.3 and 3.2.4 in this thesis). One way to 
test the effect of Rph1p on mutagenesis could be to construct a gene repair 
assay, where the generation of a frame-shift mutation within a coding region 
could restore gene function. In a diploid which is homozygous for the recessive 
mutant allele, the presence of RPH1 would be expected to reduce the revertant 
frequency since the homologous mutant allele would preferentially be used as a 
template for HRR. 
Alternatively, since the deletion of histone lysine demethylase activity of 
Rph1p was shown in publication II to significantly affect the expression of 45 
genes, it would be interesting to study the effects of the rph1-H235A mutation 
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on gene expression in a set2 background. Set2p is a histone lysine methylase 
targeting the same residue, H3K36, as Rph1p, and would therefore be expected 
to be epistatic over rph1-H235A, but presumably not over the rph1 knockout. 
Finally, the finding in publication II that the rph1-H235A mutation 
increased the expression of telomere proximal genes, but only when analysed 
as a group, suggests the possibility that H3K36 methylation influences a 
transcriptional regulation mechanism that is active close to telomeres. This 
mechanism could hypothetically involve the telomere proximate silencing 
conferred by the Sir complex (Aparicio et al., 1991). Therefore, it would also 
be interesting to investigate the effect of the rph1-H235A mutation on gene 
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